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ABSTRACT OF DISSERTATION 
 
 
REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR 
SPLICING EFFICIENCY 
 
Low density lipoprotein receptor (LDLR) is an apolipoprotein E (apoE) receptor and may 
play a role in Alzheimer’s disease (AD) development. A single nucleotide polymorphism 
(SNP), rs688, that has been identified to modulate the splicing efficiency of LDLR exon 
12 and is associated with higher cholesterol and AD in some case-control populations. 
The exon 12 deleted mRNA is predicted to produce a soluble form of LDLR that fails to 
mediate apoE uptake. To gain additional insights, in this study, I seek to understand the 
regulation of LDLR splicing efficiency. To identify functional cis-elements within LDLR 
exon 12, I mutated several conserved putative exonic splicing enhancers (ESEs) to 
neutralize their affinity to serine/arginine-rich (SR) proteins. Transfection of wild type 
(WT) or mutant LDLR minigenes in HepG2 cells was performed, and splicing efficiency 
evaluated by quantitative RT-PCR. The results showed that two functional ESEs within 
exon 12, near rs688, are critical to LDLR splicing. To identify splicing factors that 
modulate exon 12 splicing, I co-transfected an LDLR minigene and vectors encoding 
different SR proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). After 
quantifying the splicing efficiency, I found that SRp20 and SRp38 increased exon 11-
skipping.  Moreover, ectopic expression of SRp38-2 and hnRNP G increased exon 
11&12-skipping. Interestingly, the actions of hnRNP G did not require its RNA 
recognition motif (RRM). To further investigate the role of theses splicing factors on 
LDLR splicing, I quantified the expression level of these splicing factors as well as 
LDLR splicing efficiency in human brain and liver. I found that SRp38 mRNA 
expression is associated with LDLR splicing efficiency. In conclusion, this study 
discovered that rs688 is located close to the two functional ESEs within LDLR exon 12, 
and revealed a role of SRp38 in LDLR splicing efficiency. 
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 1 
CHAPTER ONE 
INTRODUCTION 
 
Alzheimer’s Disease 
 
Impact 
Alzheimer‟s disease (AD) is the most common form of dementia which is characterized 
by loss of memory and other cognitive abilities. AD is an age-related disease such that 
the prevalence of AD increases with aging. While only 0.075% of population under age 
65 have AD, 13% of population above age 65 are affected by AD in the United States. 
The number of people with the disease doubles for every 5-year age interval beyond age 
65 (Alzheimer's 2009). Twenty-five to 30 million people worldwide are estimated to 
currently suffer from AD (Ferri, Prince et al. 2005; Minati, Edginton et al. 2009) with 
about 5.3 million Americans are living with AD (Hebert, Scherr et al. 2003; Alzheimer's 
2009). In 2011, the first baby boomer will turn 65 years old. As the proportion of elders 
in the population increase, the number of people with AD is predicted to double at least 
by 2050 (Hebert, Scherr et al. 2003). Because of the demand of this disease, intensive 
caregiving is required for not only patients are affected by AD, but also their family 
members, friends, and caregivers. Additionally, people with AD are high user of 
healthcare services. The direct and indirect costs of Alzheimer's and other dementias to 
Medicare, Medicaid and businesses amount to more than $148 billion each year, much 
higher than costs for other Medicare beneficiaries (Alzheimer's 2009). An intervention 
that could delay the mean onset of AD by 5 years would reduce the expected prevalence 
by 50% after 40 years (Brookmeyer, Gray et al. 1998). Although the pathological 
mechanism behind the disease is still not completely understood, several genetic 
breakthroughs have been achieved to provide hints of the disease development and help 
understanding the biochemical pathology of the disease. The long-term goal is to prevent 
the onset or progression of the disease. 
 
Pathology 
Alzheimer‟s disease was first described by a German neuropsychiatrist, Alois Alzheimer, 
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in 1906. The patient first had strange behavioral symptoms, including a loss of short-term 
memory. After autopsy, atrophy of the brain and dilatation of the ventricles were 
observed, and vast amyloid plaque and neurofibrillary tangles were stained around 
amygdala, hippocampus and neocortex. AD is now known as a neurodegenerative disease 
characterized by loss of neurons, extracellular amyloid plaques, and intracellular 
neurofibrillary tangles. A current AD neuropathological assessment known as the 
National Institute on Aging-Reagan Institute (NIA-Reagan) criteria is base on the 
demonstration of sufficient numbers of these hallmark lesions during autopsy (Jellinger 
and Bancher 1998; Newell, Hyman et al. 1999). 
 
Amyloid plaques are extracellular insoluble fibrous aggregates of proteolytic products of 
the amyloid precursor protein (APP), an integral membrane glycoprotein. APP is 
abundantly expressed in neurons and has several roles in the development and function of 
the neurons (Mattson 1997; Young-Pearse, Bai et al. 2007; Young-Pearse, Chen et al. 
2008). APP can be processed via non-amyloidogenic or amyloidogenic pathways. When 
undergoing non-amyloidogenic processing, APP is sequentially cleaved by α-secretase 
and γ-secretase. In contrast, when APP is sequentially cleaved by β-secretase and γ-
secretase, amyloidogenic peptide is generated. Due to the slippage of γ-secretase at the 
cleavage site at the C terminal of amyloid, different species of amyloid-β peptide (Aβ) 
with variable length are produced. The major species is Aβ40 which is 40 amino acids 
long. The Aβ42, about 10% of amyloid-β peptide, is the core molecule of amyloid plaques, 
but Aβ40 is usually colocalized with Aβ42 in a plaque (Jarrett, Berger et al. 1993). 
Whether the deposition of Aβ is the cause of neuronal degeneration is still a debate (Neve 
and Robakis 1998; Small and Duff 2008; Pimplikar 2009). Recently, soluble Aβ 
oligomers or dimers have been reported to be neurotoxic and impair memory (Lesne, Koh 
et al. 2006; Haass and Selkoe 2007; Shankar, Li et al. 2008). A lot of genetic data support 
the role of APP processing in AD development, leading to an Aβ-centric view of AD. A 
phase III clinical trial of a compound inhibiting Aβ aggregation has failed to prevent AD 
progression (Gauthier, Aisen et al. 2009). However, several clinical trials of vaccine 
targeting Aβ are ongoing (Rafii and Aisen 2009). These results would help to clarify the 
role of amyloid in AD.  
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Neurofibrillary tangles (NFTs) are intracellular aggregates of microtubule-associated 
protein tau (MAPT) that is abnormally hyperphosphorylated and arranged in a form of 
paired helical filaments (Grundke-Iqbal, Iqbal et al. 1986; Kosik, Joachim et al. 1986). 
NFT is not only seen in AD, but also in a class of neurodegenerative diseases called 
taupothies, including Pick‟s disease, frontotemporal dementia, and Down syndrome. The 
number of NFTs directly correlates with the presence and the degree of dementia in AD 
(Alafuzoff, Iqbal et al. 1987; Arriagada, Growdon et al. 1992). Tau is highly expressed in 
neurons and stabilizes microtubules within cells (Drechsel, Hyman et al. 1992). 
Hyperphosphorylated tau fails to bind microtubules, causing microtubule dissociation and 
hence neurodegeneration (Brunden, Trojanowski et al. 2009).Whether NFTs contribute to 
the AD development or are just a secondary phenomenon has been disputed, since tau 
knockout mice develop a functional nervous system. However, mutations in MAPT gene 
that result in frontotemporal dementia with parkinsonism-17 (FTDP-17) have shown that 
tau can be pivotal in neurodegenerative process (Hong, Zhukareva et al. 1998). The link 
between Aβ and NFT is not clear, but the prevailing viewpoint is that the Aβ initiates a 
cellular cascade that results in tau aggregation (Hardy and Selkoe 2002). 
 
Genetics 
While the majority of AD cases occur after age 65, about 5% of AD cases develop before 
age 65, referred to as early-onset AD. Sometimes the patients are as young as age 30 
(Hardy and Selkoe 2002). 
 
Three genes have been linked to early-onset familial AD (FAD), including APP, 
presenilin 1 (PSEN1), and presenilin 2 (PSEN2). The first genetic cause of AD identified 
is a mutation of APP (Goate, Chartier-Harlin et al. 1991). Some rare missense mutations 
located close to the α-, β-, or γ-secretase cleavage site in APP change APP processing, 
increase Aβ production (Citron, Oltersdorf et al. 1992; Cai, Golde et al. 1993; Suzuki, 
Cheung et al. 1994), and thereby cause early-onset AD. Another example of mutation in 
APP resulting in AD is Down‟s syndrome. APP is located in chromosome 21, and the 
Down‟s syndrome is characterized by the presence of an extra copy of genetic material 
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on the chromosome 21, either in whole (trisomy 21) or part. All patients with trisomy 21 
develop AD at early age because they get an extra APP gene as well, resulting in over-
production of Aβ. The causal relationship is supported by a case involving a patient with 
Down‟s syndrome which resulted from partial translocation of chromosome 21 without 
APP and the patient did not develop AD (Prasher, Farrer et al. 1998). PSEN1 and PSEN2 
are located in chromosomes 14 and 1 respectively. Their gene products are essential 
components of γ-secretase. Mutations on the two genes resulting in Aβ over-production 
are also genetic causes of familial AD (Schellenberg, Bird et al. 1992; Levy-Lahad, 
Wijsman et al. 1995; Duff, Eckman et al. 1996). Interestingly, all the three genes linked 
to early-onset AD are involved in APP processing. These genetic findings lead to 
“amyloid hypothesis” that accumulation of Aβ is the primary cause of AD. 
 
Apolipoprotein E (APOE) has been linked to late-onset AD which accounts for about 
95% of AD cases and occurs after age 65. APOE gene has three polymorphic alleles as 
2, 3, and 4. 3 is the most (77%) and 2 the least common allele (Mahley 1988). 4 
allele is a major genetic risk for late-onset AD (Strittmatter, Saunders et al. 1993). The 4 
allele frequency is about 15% in general population but increase to 40% in patients with 
AD. Individuals with one 4 allele have three to four fold higher chance to develop AD 
than those without 4 allele (Corder, Saunders et al. 1993). APOE is a constituent of 
many lipoproteins that transport cholesterol and lipids throughout the circulatory system 
and between cells. The blood-brain barrier (BBB) limits the passage of macromolecules 
and lipoproteins particles between the peripheral and the central nervous system. The 
nervous system is capable of de novo synthesis of lipid molecules, but can also 
redistribute lipoproteins locally for their lipid requirements (Pitas, Boyles et al. 1987; 
Poirier, Baccichet et al. 1993). In the brain, APOE is mainly produced by glial cells 
(Boyles, Pitas et al. 1985; Elshourbagy, Liao et al. 1985). Packed with lipoproteins, 
APOE is a ligand that is recognized by cell receptors that mediate the endocytosis of 
lipoprotein particles. APOE binds to a group of receptor known as the low density 
lipoprotein receptor (LDLR) family (Herz and Bock 2002; Herz and Chen 2006) 
 
Several genes have been weakly linked to the late-onset AD, for example, LDLR-related 
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protein (LRP) (Kang, Saitoh et al. 1997; Beffert, Arguin et al. 1999) and 2-
macroglobulin ( 2M) (Blacker, Wilcox et al. 1998; Liao, Nitsch et al. 1998), but none has 
shown as solid association as APOE 4 allele. The mechanism of APOE 4 allele being 
pathogenic to AD is still not fully understood, but several pathways have been 
investigated.  
 
APOE and AD 
 
Cholesterol Metabolism 
AD may be a result of dysfunction of cholesterol metabolism in brain. The brain contains 
25% of all unesterified cholesterol in a body while accounting for only 2% of the body 
mass (Herz and Bock 2002). Cholesterol is an essential component of cell membranes 
and myelin sheaths, and is involved in synapse formation and plasticity (Pfrieger 2003). 
The primary function of APOE is to transport cholesterol and lipid molecules. Astrocyte-
derived APOE-containing cholesterol is essential for synapse formation (Mauch, Nagler 
et al. 2001). Some reports shown that the use of statins, a cholesterol-lowing drug, 
decreases risk for AD, suggesting an association between cholesterol metabolism and AD 
risk (Jick, Zornberg et al. 2000; Wolozin, Kellman et al. 2000), although some following 
studies did not support the statement (Shobab, Hsiung et al. 2005). Whether the three 
APOE isoforms have functional differences regarding cholesterol metabolism is not clear, 
but some evidence has shown that APOE4 might be less efficient in transporting brain 
cholesterol (Rapp, Gmeiner et al. 2006) and promoting cholesterol efflux (Michikawa, 
Fan et al. 2000). The lower efficiency of cholesterol metabolism might cause synaptic 
and neuronal dysfunction in an A -independent way. 
 
Cholesterol may also influence AD development in an A -dependent way. Both 
cholesterol and statins, cholesterol-lowing drugs, have been shown to modulate APP 
processing with lower cholesterol level resulting in lower A  production (Simons, Keller 
et al. 1998; Simons, Schwarzler et al. 2002). The results may be related to that cholesterol 
is enriched in lipid rafts where APP processing by - and -secretase is favored 
(Thinakaran and Koo 2008). 
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Several studies have shown that APOE expression increases after injury in the brain 
(Hayashi, Kamada et al. 2006; Xu, Bernardo et al. 2006). The injury-induced 
upregulation of APOE may help to redistribute lipids and strengthen APOE-mediated 
signaling for synaptic and neuronal repairs. Glia-derived
 
lipoprotein particles protect 
central nervous system neurons from apoptosis by a receptor-mediated
 
signaling pathway, 
and APOE3 shows a greater protective effect than APOE4 (Hayashi, Campenot et al. 
2007). In addition, APOE3 increases neurite outgrowth while APOE4 either decreases 
outgrowth or has no effect (Nathan, Bellosta et al. 1994; Holtzman, Pitas et al. 1995). 
These results indicate that APOE4 is less effective than APOE3 in maintaining and 
repairing neuronal synapses. Possibly in aged brains, A  oligomers or misfolded tau or 
other neuronal stresses cause neuron damage, and APOE4 is less effective in repairing 
injured neurons, thereby resulting in late-onset AD. 
 
A  Production 
APOE and its receptors influence APP processing that produces A , and may hence 
contribute to AD development. Reports demonstrate that an APOE receptor, LRP, 
interacts with APP either by direct binding extracellularly (Knauer, Orlando et al. 1996) 
or via adaptor protein such as FE65 which binds to both LRP and APP intracellularly 
(Trommsdorff, Borg et al. 1998; Pietrzik, Yoon et al. 2004). Because of the faster rate of 
LRP endocytosis, this interaction accelerates APP endocytic trafficking to acidic 
endosomes (Perez, Soriano et al. 1999) where -secretase is abundantly present and 
active (Cole and Vassar 2007). Therefore, the increased distribution of APP in 
endosomes result in increased A  production (Ulery, Beers et al. 2000; Cam, Zerbinatti et 
al. 2005). Overexpression of a functional LRP minireceptor in neurons causes an age-
dependent increase in soluble brain A  (Zerbinatti, Wozniak et al. 2004). APOE4 has 
been shown to result in more A  production than APOE3. In cultured neurons, ectopic 
expressions of APP and APOE4 increases A  production more than APOE3, and the 
difference is avoided by preincubating cells with receptor-associated protein (RAP), an 
LRP binding protein, indicating that the effect is LRP-dependent (Ye, Huang et al. 2005). 
In addition to LRP, three other APOE receptors have been shown to modulate APP 
processing. LRP1B reduces A  production because of its slow endocytosis rate (Cam, 
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Zerbinatti et al. 2004). APOER2 reduces A  production when F-spondin, an adaptor 
protein which bridges extracellular interaction between APP and APOER2, is present 
(Hoe, Wessner et al. 2005). Deletion of Sortilin-related receptor with A-type repeats 
(SORLA) in mice increases A  concentration, suggesting that SORLA promotes APP 
trafficking to Golgi compartment and hence reduces A  production (Andersen, Reiche et 
al. 2005).  
 
A  Clearance 
Amyloid plaques are a pathological feature of AD, and probably impaired A  clearance 
is a pathogenic event for AD. A  can be removed from the brain through two pathways: 
receptor-mediated clearance by cells or by drainage though the blood-brain barrier (BBB), 
and endopeptidase-mediated degradation. 
 
Several reports shown that APOE is involved in A  clearance through APOE receptors. 
APOE and LRP and other LRP ligands have been identified in amyloid plaques (Rebeck, 
Reiter et al. 1993). APOE binds to A  via its c-terminal domain overlapping with lipid-
binding region. Therefore, A  binding to APOE compromises the lipid binding function 
of APOE (Strittmatter, Weisgraber et al. 1993; Tamamizu-Kato, Cohen et al. 2008). 
Furthermore, A  binding to APOE influences APOE binding to APOE receptors. For 
example, the presence of A  increases binding and internalization of APOE-liposome to 
hippocampus neurons (Beffert, Aumont et al. 1998). Compared to APOE4, APOE3 has 
been shown to have a higher affinity for A  and to clear A  through receptors on the cell 
surface more efficiently, and hence overall result in lower A  accumulation (LaDu, 
Falduto et al. 1994; Holtzman, Bales et al. 1999; Holtzman, Bales et al. 2000). In addition 
to be cleared by cell endocytosis and lysed, A  can be removed from the brain by 
crossing the BBB in a receptor-dependent way. Recently, a report shown that at the BBB, 
A  binding to APOE4 redirects its clearance form LRP to very low-density lipoprotein 
receptor (VLDLR) which has s slower internalization rate. Therefore, VLDLR clears A -
APOE4 complex less efficiently than LRP and VLDLR clear A -APOE2 or A -APOE3 
complexes at the BBB (Deane, Sagare et al. 2008).  
 8 
 
A  can be processed directly by endopeptidase-mediated degradation. Several A -
degrading enzymes have been identified (Leissring 2008), but neprilysin (NEP) and 
insulin-degrading enzyme (IDE) are the two most studied A  protease that are expressed 
in both neurons and vascular cells (Bu 2009). Expression of IDE is reduced when APOE 
4 allele is present (Du, Chang et al. 2009), and APOE3 promotes A  degradation by 
NEP and IDE more efficiently than APOE4 (Jiang, Lee et al. 2008). These results 
indicate that APOE may also play a role in A  clearance by proteolytic degradation. 
 
Tau Phosphorylation 
Hyperphosphorylated tau is the main component of neurofibrillary tangles (NFTs) and is 
toxic to neurons, suggesting that dysregulation of tau may contribute to AD development 
as well. The presence of APOE 4 allele is associated with higher content of NFTs in the 
neocortex (Nagy, Esiri et al. 1995; Ohm, Kirca et al. 1995). Overexpression of APOE4 in 
neurons but not in astrocytes increases tau phosphorylation in transgenic mice (Tesseur, 
Van Dorpe et al. 2000; Brecht, Harris et al. 2004). APOE normally expresses in 
astrocytes, not neurons, but APOE expression in neurons after injury has been reported 
(Aoki, Uchihara et al. 2003). Possibly in stressed AD brains, abnormal APOE expression 
in neurons increases tau phosphorylation (Bu 2009). The mechanism of how APOE 
influences tau phosphorylation is not clear. One hypothesis is that APOE isoforms may 
differentially regulate APOE receptor-mediated signaling pathway that thereby modulates 
the function of tau kinases and phosphatases, and causes tau phosphorylation 
differentially (Bu 2009). Another hypothesis is that the C-terminal-truncated fragments of 
APOE enter the cytosol and interact directly with tau and influence tau phosphorylation 
status (Brecht, Harris et al. 2004).  
 
APOE Receptors: LDLR family 
 
APOE binds to members of the low density lipoprotein receptor (LDLR) family. This 
family represents a group of modular type-I-transmembrane proteins that recognize and 
bind several ligands in the extracellular space. Once ligands bind, they initiate 
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endocytosis that transfers the ligand-receptor complex to the endosomal/lysosomal 
compartments within the cell. After releasing the cargo, the receptors recycle back to the 
cell surface, and the ligands are further processed or degraded. In addition to function as 
endocytosis receptors, several LDLR family members also play an important role in a 
variety of cellular signaling pathways (Jaeger and Pietrzik 2008).  
 
The LDLR family includes LDLR, LRP (a.k.a. LRP1), LRP1B, megalin (a.k.a. gp330 or 
LRP2), multiple epidermal growth factor like domains 7 (MEGF7, a.k.a. LRP4), 
VLDLR, Apolipoprotein E receptor-2 (ApoER2, a.k.a. LRP8), LRP5, LRP6 and sortilin-
related receptor with A-type repeats (SORLA, a.k.a. SORL1 and LR11). The members 
contains five characteristic domains: (a) ligand binding type cysteine-rich repeats, (b) 
epidermal growth factor type cysteine-rich repeats, (c) YWTD-containing -propeller 
domain (Springer 1998; Jeon, Meng et al. 2001), (d) a single membrane spanning 
domain, and (e) a cytoplasmic tail. Except LRP5, LRP6 and SROLA, the cytoplasmic 
tails of all other members contain one or more „NPxY‟ (Asp-Pro-any amino acid-Tyr) 
motifs which function in recruitment of adaptor proteins containing phosphotyrosine 
binding (PTB) domains. In contrast, the cytoplasmic tails of LRP5 and LRP6 contain five 
„PPPSP‟ (Pro-Pro-Pro-Ser-Pro) motifs and SORLA contains one GGA-binding motif. 
The PPPSP motif is a target sites for glycogen synthase kinase 3 (GSK3) and essential for 
signaling pathway (Cselenyi, Jernigan et al. 2008). The GGA-binding motif is a target 
site for GGA proteins (Golgi associated, gamma-adaptin ear containing,
 
ADP-
ribosylation factor binding protein), required for receptor trafficking. Another optional 
module is the O-linked sugar domain, which is found in some receptors immediately 
preceding the membrane-spanning segment (Herz and Bock 2002; Bu 2009) (Figure 1.1). 
 
Although the LDLR family members may recognize distinct ligands, they share an ability 
to bind the receptor-associated protein (RAP). RAP functions as a chaperone for all the 
receptors in the endoplasmic reticulum where it facilitates proper folding (Bu, Geuze et 
al. 1995; Obermoeller-McCormick, Li et al. 2001) as well as prevents the premature 
interaction of ligands with receptors (Willnow, Armstrong et al. 1995; Willnow, 
Rohlmann et al. 1996).  
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LDLR and LRP are the two major APOE receptors in the brain. Deletion of the Ldlr gene 
in mice increases APOE levels in the brain parenchyma and cerebrospinal fluid (CSF) 
(Fryer, Demattos et al. 2005), and similarly, conditional deletion of the Lrp1 gene in 
mouse forebrain neurons increases APOE levels (Liu, Zerbinatti et al. 2007). In contrast, 
overexpression of a functional LRP1 minireceptor in the mouse brain decreases brain 
APOE levels (Zerbinatti, Wahrle et al. 2006). These results indicate that LDLR and LRP 
play an important role in APOE metabolism. However, they may regulate APOE and 
lipid metabolism differentially. While deletion of either Lrp1 gene or Ldlr gene increases 
APOE levels, brain cholesterol levels are unchanged in Ldlr-knockout mice (Fryer, 
Demattos et al. 2005) but reduced in Lrp1-knockout mice (Liu, Zerbinatti et al. 2007) 
APOE–lipoprotein particles secreted by astrocytes have higher affinity for LDLR than for 
LRP1 (Fryer, Demattos et al. 2005), whereas APOE-enriched lipoprotein particles and 
CSF-isolated HDL particles
 
bind more prone to LRP1 than to LDLR (Kowal, Herz et al. 
1990; Fagan, Bu et al. 1996). In this study, I focus on LDLR because our lab has 
previously identified several LDLR splice variants that may be associated with AD (see 
below). 
 
LDLR  
 
Gene Structure 
The LDLR gene (GeneID: 3949) is 45 kb and localized on chromosome 19p13.1-13.3. 
The gene consists of 18 exons, which correspond closely to the structural units of the 
protein. LDLR is a striking example of a mosaic protein encoded by a gene that was 
assembled by exon shuffling (Sudhof, Goldstein et al. 1985). The exon 1 encodes 168 bp 
upstream of the initial methionine codon and the signal sequence. Cysteine-rich repeats 
1-2 and 6-7 of the ligand-binding domain are each encoded by individual exons. The 
other repeats 3-5 are all encoded by exon 4. The epidermal growth factor (EGF) repeats 
are each encoded by individual exons. Exons 9-13 encode the -propeller domain. The 
O-linked sugar domain is encoded by exon 15. The transmembrane domain is interrupted 
by a single intron. Exon 17 encodes the C-terminal half of the transmembrane domain 
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and a part of the cytoplasmic domain. The last exon encodes the remaining cytoplasmic 
domain and the 3′-untranslated region of the mRNA (Kim, Magoori et al. 1997) (Figure 
1.2). The mRNA is 5.3 kb and encodes a protein of 860 amino acids (Yamamoto, Davis 
et al. 1984).  
 
The LDLR gene promoter region contains regulatory elements consisting of three 
imperfect direct repeats of 16 bp. Repeat 1
 
(R1) and repeat 3 (R3) contain Sp1-binding 
sites that support
 
basal transcriptional activity. Repeat 2 (R2) contains a sterol response 
element (SRE), a binding site for SRE-binding
 
protein (SREBP). This transcription factor 
is synthesized in the endoplasmic reticulum as an inactive precursor, and is released to 
the nucleus by sterol-sensitive
 
proteolysis (Sakai, Rawson et al. 1998) to upregulate 
transcription of LDLR and other genes in the cholesterol pathway (Sekar and Veldhuis 
2004; Attie and Seidah 2005).  
 
Function 
LDLR plays a central role in cholesterol homeostasis. The LDLR is the cell surface 
receptor that regulates plasma cholesterol by mediating endocytosis of LDL, the major 
cholesterol transport protein in human plasma. LDL particles carry approximately 65-
70% of plasma cholesterol in humans (Jeon and Blacklow 2005). Each LDL particle 
contains a highly-hydrophobic core consisting of esterified cholesterol molecules 
surrounded by a shell of phospholipids and unesterified cholesterol, as well as a single 
apolipoprotein B-100 (APOB-100). The LDLR also binds to lipoproteins that contain 
multiple copies of APOE, such as -migrating forms of very low-density lipoprotein (β-
VLDL), or certain intermediate and high-density lipoproteins (HDL) (Innerarity and 
Mahley 1978; Weisgraber, Innerarity et al. 1978).  
 
LDLR binds to the APOB- or APOE-containing lipoproteins and initiates endocytosis via 
clathrin-coated pits, where the receptor molecules cluster on the cell surface (Anderson, 
Brown et al. 1977; Anderson, Goldstein et al. 1977). The complexes are then delivered to 
endosomes, where the lipoprotein particles are released because of the low-pH 
environment. The receptors are then recycled to the cell surface, whereas the lipoprotein 
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particles are processed upon fusion with lysosomes. The APOB or APOE protein is 
degraded to amino acids and the cholesterol esters are hydrolyzed to fatty acids and 
cholesterol. The free cholesterol inhibits expression of LDLR and 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting step in cholesterol 
synthesis, forming a negative feedback regulation. Simultaneously, a reciprocal 
stimulation of cholesterol ester synthesis favors storage and utilization of excess 
cholesterol (Brown, Dana et al. 1975; Goldstein and Brown 2009). 
 
LDLR and Familial Hypercholesterolemia 
Familial hypercholesterolemia (FH) is a disease characterized by abnormal elevated 
concentration of plasma LDL and cholesterol, which lead to excess cholesterol deposition 
in tissues, resulting in accelerated atherosclerosis and increased risk of premature 
coronary heart disease (Soutar and Naoumova 2007). A series of papers by Drs. 
Goldstein and Brown demonstrated that FH results from defects in metabolism of LDL 
via the LDLR-mediated endocytosis, mostly caused by a loss-of-function mutation in the 
LDLR gene (Brown and Goldstein 1974; Goldstein and Brown 1974; Goldstein, Dana et 
al. 1975). FH is an autosomal dominant genetic disorder with a gene-dosage effect. While 
heterozygous FH is treatable with cholesterol-lowing medicine, homozygous FH shows 
weak response to medicine. Homozygous FH is very rare (  1/10
6
), whereas the 
frequency of heterozygous FH in most populations is about 1/500 and more than 1000 
LDLR mutant alleles have been identified in FH subjects. These genetic variants have 
been reviewed (Hobbs, Brown et al. 1992) and listed online at http://www.ucl.ac.uk/fh/ 
(Wilson, Gahan et al. 1998) and http://www.umd.necker.fr/LDLR/research.html 
(Villeger, Abifadel et al. 2002).  
 
LDLR and AD 
Several findings indicate that LDLR may be involved in AD development. First, the 
LDLR gene is located on chromosome 19p13.1-13.3, including a region that has been 
reported to link with late-onset AD (Wijsman, Daw et al. 2004). Second, LDLR is a main 
APOE receptor in the brain (Herz and Bock 2002). APOE influences A  production (Ye, 
Huang et al. 2005) or clearance in a receptor-dependent manner (Holtzman, Bales et al. 
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1999; Holtzman, Bales et al. 2000). In addition, deletion of Ldlr gene in mice increases 
APOE levels in the brain (Fryer, Demattos et al. 2005), indicating that LDLR may affect 
APOE function even through a receptor-independent pathway. Since APOE allele 
variants are associated with AD (Strittmatter, Saunders et al. 1993), LDLR variants may 
contribute to AD as well. Third, LDLR is intimately linked with cholesterol homeostasis, 
and cholesterol metabolism has emerged as an AD modulator. Individuals with elevated 
levels of plasma cholesterol have higher susceptibility to AD (Jarvik, Wijsman et al. 
1995). Reducing cholesterol level decreases A  production (Simons, Keller et al. 1998). 
Forth, LDLR-deficient mice show spatial learning deficits (Cao, Fukuchi et al. 2006), 
which is a pathological feature of AD patients (Swainson, Hodges et al. 2001). As such, 
LDLR is a considerable candidate to investigate for AD. 
 
LDLR Mutations 
Based on the phenotypic effect on the protein, LDLR mutations are divided into five 
classes (Hobbs, Russell et al. 1990; Jeon and Blacklow 2005). Class 1 mutations result in 
no protein synthesis due to disruptions of the promoter sequence, nonsense, frameshift, or 
splicing mutations (null alleles). Class 2 mutations disrupt transport of the LDLR from 
the endoplasmic reticulum to the Golgi apparatus due to mutations in the ligand-binding 
and EGF precursor regions (transport-defective alleles). Class 3 mutations are also 
primarily found in the ligand-binding and EGF precursor regions but interfere with cell 
surface binding of the receptor to LDL (binding-defective alleles). Class 4 mutations in 
the cytoplasmic and membrane-spanning domains inhibit the clustering of LDL receptors 
on the cell surface, so that the bound LDL particle is not internalized (internalization-
defective alleles). Class 5 mutations in the epidermal growth factor precursor region 
prevent the proper release of LDL particles in the endosome and, as a result, the LDL 
receptor is not recycled to the cell surface (recycling-defective alleles.). 
 
Some of the mutations result in LDLR splicing difference. For example, a mutation 
located in the end of LDLR intron 12 changes the consensus 3‟ splice site, resulting in 
aberrant splicing (Nissen, Hansen et al. 1997). A study aimed to characterize LDLR 
mutations of FH in Spain families, and found 14 splicing mutations that affect splicing 
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donor or acceptor consensus sequences are expected to influence LDLR splicing (Mozas, 
Castillo et al. 2004). In addition to mutations located in splice sites, polymorphisms that 
affect splicing regulatory element sequences may change LDLR splicing efficiency. 
 
Regulation of Splicing  
 
Alternative splicing is a major mechanism for regulating gene expression and 
contributing to protein diversity. Estimates of the proportion of human genes that are 
alternatively spliced range from 35-60% (Mironov, Fickett et al. 1999; Modrek and Lee 
2003). Alternative splicing is characterized by utilization of different splice sites. 
Splicing requires that small nuclear ribonucleoproteins (snRNPs) such as U1, U2, U4, U5 
and U6, recognize a conserved 5‟ splice site, branch point and 3‟ splice site to assemble a 
spliceosome (Hastings and Krainer 2001). If these sequences vary from consensus 
sequence, non-snRNP splicing factors are required to achieve efficient splicing. 
 
The two major non-snRNP splicing factor families are the serine/arginine-rich (SR) 
protein family and heterogeneous nuclear ribonucleoprotein (hnRNP) family. The SR 
proteins consist of one or two RNA recognition motifs (RRMs) and a carboxyl-terminal 
domain enriched with serine/arginine repeats (RS domain). The RRMs determine RNA 
binding specificity, whereas the RS domain mediates protein-protein interactions 
(Caceres and Kornblihtt 2002). Conventionally, SR proteins recognize exonic splicing 
enhancers (ESEs) and recruit splicing machinery close to the exon/intron boundary and 
therefore enhance splicing; a minority of SR proteins act to inhibit splicing (Lin and Fu 
2007). 
 
In contrast, hnRNPs were first described as a major group of chromatin-associated RNA-
binding proteins (Krecic and Swanson 1999). These proteins consist of at least one RNA 
binding motif such as an RNA recognition motif (RRM), hnRNP K homology (Defesche, 
Schuurman et al.) domain or a arginine/glycine-rich (RGG) box as well as auxiliary 
domains for protein-protein interactions (He and Smith 2009). HnRNPs recognize ESEs 
or exonic splicing silencers (ESS) (Auclair, Busine et al.) to regulate splicing efficiency.  
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Additionally, intronic splicing enhancer (ISE) and intronic splicing silencer (Puissant and 
Houdebine) have also been identified, but the mechanism is not as well understood 
(reviewed in (Hastings and Krainer 2001; Black 2003)). 
 
Specific Aims 
 
Our lab previously showed that rs688 modulates LDLR exon 12 splicing efficiency (Zhu, 
Tucker et al. 2007; Zou, Gopalraj et al. 2008). Located in LDLR exon 12, rs688 is a 
single nucleotide polymorphism (SNP), with a major C and minor T alleles. In Caucasian 
populations, the minor allele carriers, i.e. C/T or T/T individuals, represent 60–65% of 
the population. The frequency of rs688T allele carriers in other races varies from 0-17% 
in African populations to 17-34% in Asian populations. Association studies revealed that 
rs688 associated with higher cholesterol in pre-menopausal women (Zhu, Tucker et al. 
2007) and with Alzheimer‟s disease in men (Zou, Gopalraj et al. 2008). I interpret the 
results as suggesting that enhancing LDLR splicing will lower cholesterol level and 
decrease AD risk. However, the mechanism of rs688 modulating LDLR exon 12 splicing 
and the regulation of LDLR splicing are still unclear. Therefore, I propose two specific 
aims.  
 
1) To identify functional ESE(s) within LDLR exon 12. 
Rs688 modulates LDLR splicing efficiency and the change from rs688C to rs688T allele 
is predicted to influence splicing regulatory elements affinity to splicing factors. Hence, I 
hypothesize that rs688 is located in or close to functional ESE(s) and thereby influence 
LDLR exon 12 splicing. 
 
2) To identify splicing factors that modulate LDLR splicing efficiency. 
To further investigate the regulation of LDLR splicing, I proposed to identify splicing 
factors modulating LDLR splicing that may help to understand the involvement of LDLR 
splicing physiologically and pathologically.  
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Figure 1.1 LDLR family members 
Member of the LDLR family and their characteristic modules are shown. The furin 
cleavage sites in LRP1 and LRP1B are indicated by arrows. The four clusters of ligand-
binding repeats in LRP1 are labeled (I–IV). Highlighted in blue are the two extra 
sequences in LRP1B (compared with LRP1).  
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews Neuroscience] 
Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, 
pathogenesis and therapy. Nat Rev Neurosci 10(5): 333-44, copyright (2009) 
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Figure 1.2 Exon organization and protein domains of the human LDLR 
The six functional domains of the three proteins are labeled in the lower portion of the 
figure. The ligand-binding repeats are numbered, and the EGF repeats are lettered A-C. 
5′- and 3′-untranslated regions are indicated by solid lines. The positions at which introns 
interrupt the coding region are indicated by arrowheads. Exon numbers are shown 
between the arrowheads. Chr., chromosome; EGF, epidermal growth factor. 
Reprinted by permission from American Society for Biochemistry and Molecular 
Biology: [Journal of Biological Chemistry] Kim, D. H., K. Magoori, et al. (1997). 
Exon/intron organization, chromosome localization, alternative splicing, and transcription 
units of the human apolipoprotein E receptor 2 gene. J Biol Chem 272(13): 8498-504, 
copyright (1997) 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © I-Fang Ling 2009 
 18 
CHAPTER TWO 
IDENTIFICATION OF FUNCTIONAL EXONIC SPLICING ENHANCER  
IN LDLR EXON 12 
 
Introduction 
 
Alternative splicing is an important mechanism of gene expression regulation and 
contributes to protein diversity. Approximately, 70-80% of human genes are alternatively 
spliced (Johnson, Castle et al. 2003; Kampa, Cheng et al. 2004; Clark, Schweitzer et al. 
2007). For efficient splicing, most introns require a conserved 5‟ splice site and a branch 
point sequence followed by a polypyrimidine tract and a 3‟splice site. Small nuclear 
ribonucleoproteins (snRNPs) recognize these regions and assemble spliceosome. 
Nevertheless, other non-snRNP splicing factors are involved in the process as well. For 
example, serine/arginine-rich (SR) proteins conventionally recognize exonic splicing 
enhancer (ESE) and recruit splicing machinery close to the exon/intron boundary, thereby 
enhancing splicing efficiency. The SR proteins consist of one or two RNA recognition 
motifs (RRMs) and a carboxyl-terminal domain enriched with serine/arginine repeats (RS 
domain). The RRMs determine RNA binding specificity, whereas the RS domain 
mediates protein-protein interactions (Caceres and Kornblihtt 2002). In contrast, 
heterogeneous nuclear ribonucleoproteins (hnRNPs) recognize exonic splicing silencer 
(Auclair, Busine et al.) and inhibit splicing. Additionally, intronic splicing enhancer (ISE) 
and intronic splicing silencer (Puissant and Houdebine) have also been identified, but the 
mechanism is not as well understood (reviewed in (Hastings and Krainer 2001; Black 
2003)). 
 
The interactions between some SR proteins and their specific ESE sequences have been 
identified in recent years. Cartegni et al. used a method called Systematic Evolution of 
Ligands by Exponential enrichment (SELEX) (Tuerk and Gold 1990) to identify ESE 
motifs specific for four SR proteins including SF2/ASF, SC35, SRp40, and SRp55, and 
developed an online ESE annotation tool called ESEfinder 
(http://rulai.cshl.edu/tools/ESE2/) (Cartegni, Wang et al. 2003). Fairbrother et al. 
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compared large sets of human gene sequence and identified 10 predicted ESE motifs 
which are enriched in human exons relative to introns and are significantly more frequent 
in exons with weak (non-conserved) splice sites than in exons with strong (conserved) 
splice sites. They developed an online tool called RESCUE-ESE 
(http://genes.mit.edu/burgelab/rescue-ese/) (Fairbrother, Yeh et al. 2002; 
Fairbrother, Yeo et al. 2004). Although there are other mechanisms of splicing regulation, 
ESEs appear most prevalent and these programs provide a reliable method to predict 
potentially functional ESEs of interested exons. 
 
Changes in RNA sequence that disrupt functional regulatory cis-elements resulting in 
aberrant splicing can cause human diseases (reviewed in (Cooper, Wan et al. 2009; Tazi, 
Bakkour et al. 2009)). For example, mutations N279K and Delta280K, within exon 10 of 
MAPT (microtubule-associated protein tau) disrupt an ESE, causing exon 10 skipping 
and contributing to frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17) (D'Souza and Schellenberg 2006). Another example is spinal muscular 
atrophy, which is caused by mutations within SMN1 (survival of motor neurons 1); 
although SMN2 differs from SMN1 by only a single base change, this base change 
disrupt an ESE in exon 7 of SMN2, resulting in exon 7 skipping, and therefore SMN2 
cannot compensate for the loss of SMN1 (Lorson, Hahnen et al. 1999). Targeting the 
splicing regulation can be an alternative mean for human disease therapy. 
 
Our lab previously identified a single nucleotide polymorphism (SNP), rs688, which 
modulates low-density lipoprotein receptor (LDLR) exon 12 splicing efficiency and is 
associated with higher cholesterol in pre-menopausal women (Zhu, Tucker et al. 2007) 
and with Alzheimer‟s disease in men (Zou, Gopalraj et al. 2008). However, the 
mechanism and the regulation of exon 12 splicing are still unclear. We hypothesized that 
the rs688 can modulate LDLR splicing efficiency because it locates within or close to 
functional ESE(s) in LDLR exon 12. Here, to identify functional ESEs within LDLR 
exon 12, I performed a serious of mutations that neutralize affinity of predicted ESEs to 
associated SR proteins. I found two neighboring ESEs that flank rs688 and are critical to 
LDLR splicing.  
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Materials and Methods 
 
Cell culture 
HepG2 (human hepatocellular carcinoma) cells were cultured in Dulbecco‟s modified 
Eagle‟s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin⁄streptomycin at 37°C in a humidified 5% CO2-95% air atmosphere. 
 
Construction of LDLR minigenes 
An LDLR minigene containing exons 9-14 with rs688C or rs688T in a pcDNA3.1 
backbone was previously described (Zhu, Tucker et al. 2007). I also created an additional 
LDLR minigene containing exon 12 in pSPL3b (the kind gift from Genzyme 
Corporation, MA). In addition to exon 12, this minigene included 219 bp of 5‟ intronic 
LDLR sequence and 123 bp of 3‟ intronic LDLR sequence. This minigene was generated 
by using PCR (Platinum Taq, Invitrogen) to amplify with primers EcoRI-Intron11F 
5‟
GCGGAATTCTGAAGTTTTTCTGACCTGCA
3‟
 and BamHI-Intron12R 
5‟
CGCGGATCCATAACTCAGGTCTAAGACCT
3‟
. PCR fragments were cloned into 
pCR2.1 TOPO T/A cloning vector (Invitrogen). The TA clones and the splicing vector 
pSPL3b were digested with EcoRI/BamHI and, after gel-purification, the LDLR 
fragments were ligated into the vector. The pSPL3b backbone contains rabbit β-globin 
coding sequences separated by a portion of the intron of the HIV-tat gene (Buckler, 
Chang et al. 1991) (Burn, Connors et al. 1995). The integrity of the LDLR exon 12 
minigenes was confirmed by sequencing. 
 
Evaluation of LDLR minigene splicing 
LDLR minigene splicing efficiency was evaluated by transfecting the clones into HepG2 
cells by using FuGENE 6 as directed by the manufacturer (Roche Diagnostics, Basel, 
Switzerland). Briefly, 1.5 x 10
5
 cells were seeded in a 6-well plate in 2 ml of medium 
without antibiotics one day before performing the transfection. The next day, 2 µg of 
LDLR minigene were mixed with 6 µL of FuGENE 6 reagent in 94 µl of Opti-MEM 
(Invitrogen) and added to each cell culture. Twenty-four hours after transfection, mRNA 
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was isolated and analyzed for LDLR splicing patterns by RT–PCR as previously 
described (Zhu, Tucker et al. 2007). RNA was converted to cDNA (SuperScript III, 
Invitrogen) and sequences corresponding to LDLR minigene splice products were PCR 
amplified (Platinum Taq, Invitrogen). For the LDLR exon 9-14 minigene, PCR was 
performed with an LDLR exon 10 sense primer 
5‟
CATCGTGGTGGATCCTGTTC
3‟
 and, 
to obviate endogenous LDLR, a vector-specific antisense primer 
5‟
GGGATAGGCTTACCTTCGAA
3‟
. The PCR profiles consisted of initial denaturation 
at 94°C for 4 min, followed by cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s, 
and final extension at 72°C for 7 min. For the LDLR exon 12 minigene, PCR was 
performed with primers corresponding to the 5‟ and 3‟ -globin exons in pSPL3b, i.e., 
5‟
TCTCAGTCACCTGGACAACC
3‟
 and 
5‟
CCACACCAGCCACCACCTTCT
3‟
, 
respectively. The PCR profiles consisted of initial denaturation at 94°C for 4 min, 
followed by cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s, and final extension 
at 72°C for 7 min. The minimal number of PCR cycles necessary to discern products was 
performed, i.e. 23 cycles. PCR products were separated by polyacrylamide gel 
electrophoresis and visualized by SYBR-gold fluorescence on a fluorescence imager 
(Fuji FLA-2000). PCR product identities were determined by gel purification and direct 
sequencing (Davis Sequencing). The amount of full length and inefficiently spliced 
LDLR isoforms were quantified by fluorescence intensity. For each sample, fluorescence 
values were corrected for background and normalized for length differences among 
amplicons. The percentage of each isoform was calculated by the amount of the particular 
isoform divided by the total LDLR PCR product for that sample.  
 
Mutagenesis of conversed putative ESE 
Sequences of LDLR exon 12 across human, macaque, mouse, hamster, cow, wild boar, 
rat, and rabbit were analyzed by VISTA (http://genome.lbl.gov/vista/index.shtml) and 
ESEfinder (http://rulai.cshl.edu/tools/ESE2/) (Cartegni, Wang et al. 2003). If a 
putative ESE as defined by ESEfinder was conserved between more than five species, I 
considered it as a conserved putative ESE. Conserved putative ESEs that overlapped one 
another were considered to be a conserved putative ESE region. To diminish the binding 
affinity of conserved putative ESEs to SR proteins, a series of primers were designed that 
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reduced the original binding affinity. To verify in silico that these new sequences 
neutralized the putative ESE sequences, each was computationally evaluated by 
ESEfinder and ESE-RESCUE (http://genes.mit.edu/burgelab/rescue-ese/) 
(Fairbrother, Yeh et al. 2002). Also, to ensure that the mutations did not introduce a 
putative exonic splicing suppressor (Auclair, Busine et al.), the mutated sequences were 
analyzed by FAS-ESS (http://genes.mit.edu/fas-ess/) (Wang, Rolish et al. 2004). The 
primers listed in Table 2.2 were used to mutate the single exon LDLR minigene by using 
the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) or the LDLR exon 9-
14 minigene by using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene). 
Briefly, each LDLR minigene was denatured and annealed with either one or two 
synthetic oligonucleotide primers that contain the desired mutation, and extended by 
PfuUltra high fidelity DNA polymerase. After temperature cycling, the product was 
treated with Dpn I endonuclease which digests methylated and hemimethylated DNA, the 
parental DNA template. Then, the unmethylated vector DNA containing the desired 
mutations was transformed into XL1-Blue supercompetent cells. LDLR mutations were 
confirmed by sequencing. The mutated LDLR minigenes were transfected into HepG2 
cells and splicing efficiency evaluated by RT-PCR as described above.  
 
Prediction of RNA secondary structure 
LDLR wild type and mutated sequences were analyzed by using NIPU software 
(http://www.bioinf.uni-freiburg.de/Software/NIPU/index.html) (Hiller, Zhang et al. 
2007).  
 
Statistical analysis 
The effects of rs688 alleles on LDLR minigene splicing efficiency were evaluated by a 
paired T-test because of inter-experiment variability. The effects of the LDLR mutations 
on LDLR minigene splicing efficiency were analyzed by ANOVA with a post-hoc 
Fisher‟s Least Significant Difference (LSD) test (SPSS, version 16). 
 
Results 
 
 23 
Generation of LDLR exon 12 minigene 
To identify sequences within LDLR exon 12 that modulate its splicing efficiency, I 
cloned exon 12 and flanking intronic sequences into pSPL3b, a splicing vector wherein 
the LDLR sequence is flanked by HIV-tat intronic sequences and rabbit β-globin exons 
(Figure 2.1). I planned to use this single-exon minigene in combination with site-directed 
mutagenesis to discern exon 12 sequences that modulate exon 12 splicing. To validate the 
single exon minigene, I compared its splicing relative to a previously reported LDLR 
exon 9-14 minigene (Figure 2.2A). This comparison was performed by transfecting 
minigenes containing each rs688 allele into HepG2 cells and quantifying splicing by 
reverse-transcriptase PCR (RT-PCR). The LDLR minigene containing only exon 12 
showed a modest but significant effect for rs688 on splicing, i.e., rs688T increased the 
percentage of LDLR mRNA that lacked exon 12 (Delta 12) by 3.7 ± 0.6% (n = 3, p = 
0.009; Figure 2.2B). For the LDLR exon 9-14 minigene, the rs688T allele increased the 
percentage of LDLR mRNA that lacked exon 12 by 12.6 ± 4.6% (n = 4, p < 0.01; Figure 
2.2C). I noted that rs688 also influenced the percentage of LDLR that lacked both exons 
11 and 12 (Delta 11+12), although to a smaller effect, i.e., the rs688T allele increased the 
percentage of LDLR mRNA lacking both exon 11 and 12 by 4.5 ± 1.9% (n = 4, p < 0.01; 
Figure 2.2C). In summary, the single exon minigene demonstrates rs688 effects that are 
qualitatively similar to those seen in the exon 9-14 minigene. Hence, I proceeded to use 
the single exon minigene to identify critical exonic elements that modulate exon 12 
splicing. 
 
Identification of conserved putative ESEs 
Putative exon 12 ESEs that may modulate exon 12 splicing were identified in a two-step 
process. Exon 12 ESEs in eight species were first predicted by using ESEfinder. Then, 
these sequences were aligned by using Clustal, with sequences being considered to be 
conserved if they were consistent among at least five species. Conserved putative ESEs 
that overlapped one another were considered to be a conserved putative ESE region. Nine 
conversed putative ESE regions, R1-R9, were identified in exon 12 (Figure 2.3; Table 
2.1). The location of rs688 is within two putative SRp40 binding sites, and the change 
from C to T allele is predicted to influence the binding affinity. To distinguish these two 
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putative SRp40 binding sites even though their sequences overlapped, I considered them 
as separate ESE regions and designated them as R5 and R6 respectively.  
 
Identification of functional ESEs 
To evaluate the function of each conserved region, the LDLR minigene was mutated to 
neutralize the putative affinity of each region to SR proteins (Figure 2.4) by using site-
directed mutagenesis with particular primers (Table 2.2). Wild type (WT) and each 
mutant (MT) minigene were then transfected into HepG2 cells and the splicing efficiency 
was evaluated by RT-PCR. Most of the mutations targeting conserved putative ESE 
regions did not alter exon 12 splicing efficiency. However, MT6 and MT7 significantly 
increased the percentage of Delta 12 from 18.2 ± 5.5% in the WT LDLR minigene to 
64.3 ± 14.3% and 43.4 ± 13.1%, respectively (both p < 0.001; Figure 2.5). Hence, the 
sequences targeted in MT6 and MT7 appear critical for LDLR exon 12 splicing.  
 
To discern whether exon 12 may be skipped because of a weak splice site donor, I also 
evaluated the effects of optimizing the 5‟ splice site of intron 12 from GAGgtgtgg to a 
sequence more similar to the consensus splice donor site sequence of CAGgtragt (Mount 
1982). Hence, I generated MT10 with the sequence CAGgtgtgg and MT11 with the 
sequence GAGgtgagt (Figure 2.4). Analyzed by Alternative Splicing Database (ASD), 
these changes increased the donor site score strength from 6.67 in the WT minigene to 
7.67 for MT10 and 10.46 for MT11. When I analyzed the effects of MT10 and MT11 on 
splicing efficiency, I found that MT10 had essentially no effect on exon 12 splicing, i.e., 
the percentage of Delta 12 is 14.1 ± 0.1% (p = 0.631; Figure 2.5). However, MT11 
showed a clear trend towards decreased percentage of Delta 12, i.e., 2.6 ± 0.6% (p = 
0.077; Figure 2.5). The trend associated with MT11 may reflect the larger effect of MT11 
on the donor site score, relative to MT10. 
 
To examine whether the splicing effects of MT6 and MT7 were unique to the single exon 
minigene or applicable to a more physiologic context, I introduced the MT6 and MT7 
into the LDLR exon 9-14 minigene. I also evaluated the effects of MT5 as a negative 
control. Splicing efficiency of the larger minigenes was evaluated by RT-PCR. Similar to 
 25 
the results observed in the LDLR exon 12 minigene, MT5 had no effect on splicing, i.e., 
the percentage of delta 12 was 21.1 ± 1.7%, compared to 18.3 ± 0.3% in the WT LDLR 
minigene. In contrast, MT6 and MT7 significantly increased the percentage of delta 12 to 
46.4 ± 4.8% and 46.4 ± 5.4%, respectively (both p < 0.001; Figure 2.6). These results 
indicate that the regions 6 (c.1769 – c.1772) and 7 (c.1784 – c.1787) contain splicing 
regulatory elements that are important to exon 12 splicing. 
 
Evaluation of change in RNA secondary structure 
Although the results of these studies strongly suggest that regions 6 and 7 contain 
elements critical for splicing regulation on the basis of ESEs, I also considered the 
possibility that the mutations that were introduced may alter pre-mRNA secondary 
structure. Therefore, I evaluated whether the LDLR minigene mutations altered RNA 
secondary structures by using NIPU, which predicts RNA single-strandedness. Compared 
to the WT sequence, several mutations were predicted to diminish single-stranded 
regions, including MT2, MT4 and MT9 (Figure 4). Interestingly, these mutations did not 
alter LDLR minigene splicing. Conversely, MT6 and MT7 were not predicted to change 
the pre-mRNA secondary structure and yet strongly decreased splicing efficiency. Hence, 
the decreases in splicing efficiency observed in MT6 and MT7 were not because of 
changes on RNA secondary structure but rather likely reflect the disruption of regulatory 
motifs. 
 
Evaluation of c.1784G>A effect on LDLR mingegne splicing 
In addition to rs688, I suspected that other mutations located in or close to the functional 
ESE regions may also modulate LDLR exon 12 splicing. By searching the Universal 
Mutation Database (http://www.umd.necker.fr) (Varret, Rabes et al. 1998), I found an 
LDLR human mutation, c.1784G>A, which has been reported in Korean patients with 
familial hypercholesterolemia (Kim, Choi et al. 2004), and is located within the 
regulatory region defined by MT7. This mutation changes the encoded amino acid from 
arginine to glutamine, but is also predicted to decrease ESE affinity toward SR proteins 
by ESEfinder (Figure 2.8A). To elucidate whether this mutation influences LDLR exon 
12 splicing, I generated an LDLR exon 9-14 minigene containing the mutation, and 
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compared minigene splicing efficiency to wild type. The results revealed no significant 
change in splicing (Figure 2.8B), indicating that this mutation causes LDLR malfunction 
and familial hypercholesterolemia probably by amino acid substitution, not by aberrant 
splicing. 
 
Discussion 
 
In this study, I focused on identifying ESE regions that are functional to LDLR exon 12 
splicing. By generating mutations that disrupt binding affinity of putative ESE regions to 
SR proteins, I identified two ESE regions defined by MT6 and MT7 as critical to LDLR 
exon 12 splicing. These two ESE regions are c.1769 - c.1772 and c.1784 - c.1787 
respectively. They are separated by only 11 bp, and interestingly, rs688 at c.1773 is 
located within this 11 bp. Hence, this region appears critical for LDLR exon splicing 
efficiency.  
 
While sequence-based prediction programs such as ESEfinder, RESCUE-ESE, FAS-ESS, 
and Splicing Rainbow provide useful information regarding investigating splicing 
regulation, several concerns about this approach have arisen from this study. First, ESE 
prediction has a lot of positive results, increasing extraneous work. By using ESEfinder, 
in the 140-bp human LDLR exon 12, twenty-five putative ESEs were predicted. This is 
probably because most binding sites for splicing factors are degenerate and overlapping. 
To refine the prediction, I compared sequences crossing eight species, and identified nine 
conserved putative ESE regions. Among them, minigene analyses confirmed two to be 
functional in splicing. Second, predicted binding protein may not be the functional 
protein. The region defined by MT6 is predicted to interact with SRp40 and the region 
defined by MT7 is predicted to bind SC35 or/and SF2/ASF by ESEfinder. However, my 
work that focused on identifying splicing factors which modulate LDLR splicing found 
that ectopic expression of SRp40 or SF2/ASF did not enhance LDLR splicing, but 
decreased, indicating that other splicing factors interact with the two regulatory elements. 
Additionally, the G-rich region between the two functional ESE regions matches binding 
site for hnRNP F and H, but ectopic expression of these two splicing factor did not 
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influence minigene splicing efficiency. The inability to actualize ESE prediction has been 
reported (Lastella, Resta et al. 2004; Auclair, Busine et al. 2006). These results revealed 
the limitation of the prediction programs. Splicing regulation is more complicated than 
protein-RNA recognition that protein-protein interaction is also critical to final splicing 
decision. While keep exploring binding sites for splicing factors, work also needs to be 
done to understand the crosstalk and the regulation of the splicing factors. 
 
Another filter that can be used to refine an ESE prediction is the pre-mRNA secondary 
structure since it also contributes to exon recognition (Muro, Caputi et al. 1999; Hiller, 
Zhang et al. 2007). The majority of functional splicing regulatory elements are exposed 
in the loop of a hairpin RNA structure. When a well-defined ESE is placed in the stem of 
a RNA structure, the ESE may lose the ability to modulate splicing since the binding site 
is not exposed and therefore cannot be recognized by regulatory proteins. However, a 
functional regulatory element is not necessarily located in a single-stranded region. A few 
verified motifs are located in a double-stranded conformation. For example, an intronic 
splicing enhancer, GGGGATGGG, in growth hormone 1 (GH1) is predicted located in a 
double-stranded region by NIPU (Hiller, Zhang et al. 2007). In this study, the two ESE 
regions critical to LDLR exon 12 splicing seem to be in the latter category. By using 
NIPU, they are predicted to be located in double-stranded regions (Figure2.7). The 
mechanism of how splicing factors recognize regulatory cis-elements that are located in 
double-stranded region is still unclear.  
 
To understand the splicing regulation of LDLR exon 12 is important. First, rs688 is 
located close to the functional ESEs to modulate exon 12 splicing and associated with 
higher cholesterol and Alzheimer‟s disease in some case-control populations (Zhu, 
Tucker et al. 2007; Zou, Gopalraj et al. 2008). Knowing the mechanism to improve 
LDLR splicing efficiency may provide insight for disease therapy or even prevent disease 
development. Second, optimizing the 5‟ splice site of the LDLR intron 12 increased 
splicing efficiency close to 100% (Figure 2.5), indicating that the exon 12 is probably 
skipped because of weak splice donor site. Hence, the key of exon 12 splicing decision 
resides in the interaction between functional ESEs and the regulatory proteins. Although 
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the ESEs are predicted to bind SRp40 and SF2/ASF respectively, co-transfection of their 
expression vectors with LDLR minigene did not change the minigene splicing efficiency. 
Hence, more work is necessary to identify associated SR proteins.  
 
In this study, by mutagenesis of putative conserved ESE regions, I identified two 
functional ESE regions that are important to LDLR exon 12 splicing, and that flank 
rs688. Hence, this region is critical for LDLR exon 12 splicing. 
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Figure 2.1 Cloned LDLR exon 12 and flanking intronic sequences  
The LDLR exon 12 sequence is shown in bold upper case, and the flanking intronic 
sequences were shown in lower case. The red letter indicates the location of rs688 within 
exon 12, and the underlined sequences represent recognition sites for restriction enzymes, 
EcoRI and BamHI, respectively.  
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Figure 2.2 Rs688 effects upon LDLR exon 9-14 and exon 12 minigene 
LDLR minigenes carrying rs688C or rs688T alleles were transfected into HepG2 cells 
and mRNA was isolated after 24 hours and converted to cDNA for analyses. PCR was 
performed with primers indicated as arrows in minigene schemes (A). When LDLR exon 
12 minigene was transfected, rs688T allele significantly increased the percentage of delta 
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12 (B, mean ± SD, n = 3, p = 0.009). When LDLR exon 9-14 minigene was transfected, 
the rs688T allele significantly increased the percentage of Delta 12 and Delta 11+12 (B, 
mean ± SD, n = 4, p < 0.01). Representative gel images and quantitative results were 
shown. Each line indicated a biological replicate. 
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Figure 2.3 Identification of conserved putative ESE regions 
The putative ESEs within human LDLR exon 12 as discerned by ESEfinder are shown 
(A). Putative ESEs that were conserved in at least five of the species were considered 
putative ESE regions (B). These regions, R1 – R9, are denoted in A by underlining and in 
B by the shaded boxes. The position of rs688 is boxed. * represents a nucleotide that is 
conserved within the 8 species.  
 
 
  
 
 
 
 
 33 
 
Table 2.1 Conserved putative ESE regions in LDLR exon 12 
Putative ESEs crossing 8 species were predicted by using ESEfinder. Positions are shown 
as nucleotide numbers in LDLR exon 12. Conservation is shown as number of conserved 
species/total compared species (8), and followed by a list of species lacking the putative 
ESE. 
 
 
Conserved 
Putative 
ESE 
Region 
Position 
of 
Putative 
ESE 
Region 
Putative 
ESE 
Target 
Position 
of 
Putative 
ESE Putative ESE Sequence 
Conservation 
  
    SC35 12-19 GGCCGCCT 7/8 - mouse 
    SRp55 15-20 CGCCTC 6/8 - mouse, pig 
R1 18-22 SC35 15-22 CGCCTCTA/CGTCTCTA 7/8 - pig 
    SC35 18-25 CTCTACTG/CTTTACTG 
5/8 - mouse, 
hamster, rat 
    SRp40 20-26 
CTATTGG/CTACTGG 
/TTACTGG 8/8 
R2 31-35 SC35 30-37 
GATTCCAA/GACTCCAA 
/GACTCTAA 8/8 
R3 44-48  SRp40 41-47 
CCACTCC/CCACTCT 
/TCACTCC 6/8 - bovine, rabbit 
   SRp55 45-50 TCCATC 6/8 - mouse, hamster 
    SC35 48-55 ATCTCCAG 6/8 - human, monkey 
R4 53-56 SRp40 49-55 TCTCCAG/TCTCAAG 8/8 
    SRp55 54-59 AGCATC 7/8 - hamster 
R5 62-63 SRp40 62-68 CGTCAAC/TGTCAAC 
5/8 - hamster, 
bovine, rat 
R6 64-67 SRp40 64-70 TCAATGG/TCAACGG 8/8 
R7 79-82 SF2/ASF 75-81 AACCGGA 
5/8 - mouse, 
hamster, rat 
    SF2/ASF 78-84 CGGAAGA 6/8 – mouse, rat 
R8 92-95 SF2/ASF 91-97 TGGAGGA 7/8 - hamster 
    SRp40 113-119 TCACCCC/CCACCCC 
5/8 - bovine, pig, 
rabbit 
R9 118-121 SF2/ASF 114-120 CACCCCT 8/8 
    SRp40 119-125 CTTCTCC 6/8 - bovine, rabbit 
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Figure 2.4 Mutagenesis of conserved putative ESEs 
The mutations of conserved ESE regions are shown, with putative ESE regions in shaded 
boxes and mutation sequences in bold font on top (A). The position of rs688 is boxed. 
Upper case denotes exon 12 sequence while lower case denotes intronic sequence. 
Mutations 1-9 (MT1 to MT9) were introduced to neutralize affinity of the conserved 
putative ESE regions to SR proteins as predicted by ESEfinder (B); I ensured that a new 
ESE or ESS was not introduced by evaluating the mutant sequences with ESE-RESCUE 
and FAS-ESS as well. Mutations 10 and 11 (MT10 and MT11) were introduced to 
optimize the 5‟ splice site of LDLR intron 12. 
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Mutation Mutation Primer Sequence 
MT1 CTCCTCAGTGGCCGCGCGCTCTGGGTTGACTCCAAAC 
MT2 TGGCCGCCTCTACTGGGTTGCAGTTAAACTTCACTCCATCTC 
MT3 GGGTTGACTCCAAACTTCATGCGCTCTCAAGCATCGATGTCAAC 
MT4 CAAACTTCACTCCATCTCGGCAATCGATGTCAACGGGGG 
MT5 ATCTCAAGCATCGAAATCAACGGGGGCAACCG 
MT6 TCTCAAGCATCGATGGAGTCGGGGGCAACCGGAAG 
MT7 TGTCAACGGGGGCAACCTAGTGACCATCTTGGAGGATG 
MT8 AAGAGGCTGGCCCACCTAGCCTCCTTGGCCGTCTTTG 
MT9 CCGGAAGACCATCTTCAGTGATGAAAAGAGGCTGGCCC 
MT10 TTGGCCGTCTTTCAGgtgtggcttacg  
MT11 GGCCGTCTTTGAGgtgagtcttacgtacgagatgc 
c.1784 
G>A 
CAACGGGGGCAACCAGAAGACCATCTTGG 
 
Table 2.2 Mutation Primers 
Mutation positions are underlined and in bold font. 
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Figure 2.5 Effects of mutations of putative ESEs on LDLR exon 12 minigene 
splicing 
Wild type (WT) and mutant (MT) clones were transfected into HepG2 cells, and splicing 
efficiency was evaluated by RT-PCR. While MT1 to MT9 were targeted putative ESE 
regions, MT10 and MT11 were introduced to optimize 5‟ splice site of intron 12. The 
effects of the ESE mutations on LDLR minigene splicing are shown as representative gel 
images (A) and quantitative results (B, mean ± SD, n = 3). MT11 showed a trend towards 
increasing splicing efficiency that the percentage of delta 12 is close to 0 (p = 0.077). 
While most ESE mutations didn‟t change splicing efficiency, MT6 and MT7 significantly 
increased delta 12 (p < 0.001 and p = 0.003 respectively). 
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Figure 2.6 Effects of putative ESE mutations on LDLR exon 9-14 minigene splicing 
The effects of the ESE mutations on LDLR exon 9-14 minigene splicing are shown as 
representative gel images (A) and quantitative results (B, mean ± SD, n = 3). The results 
were similar to the effect on the LDLR exon 12 minigene. MT6 and MT7 significantly 
decreased splicing efficiency (both p < 0.001). 
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Figure 2.7 Predicted effects of mutations of putative ESEs on RNA secondary 
structure 
Wild type and mutation sequences were analyzed by NIPU which computes PU score to 
predict RNA single-strandedness. X-axis represents the sequence of LDLR exon 12, and 
Y-axis represents PU value for each position. A higher PU value indicates higher single-
strandedness. Mutated regions were highlighted in grey boxes.  
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Figure 2.8 c.1784G>A has no effect on LDLR minigene splicing 
The mutation, c.1784G>A is predicted to change ESE affinity to SR proteins (A). Red 
boxes represent ESE affinity to SF2/ASF, blue box reflects ESE affinity to SC35, and 
green box represents ESE affinity to SRp40. The c.1784G>A had no effect on LDLR 
exon 9-14 minigene splicing. Quantitative results were shown (B, mean ± SD, n = 3).  
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CHAPTER THREE 
IDENTIFICATION OF SPLICING FACTORS THAT MODULATE  
LDLR SPLICING 
 
 Introduction 
 
To achieve efficient splicing, in addition to snRNPs recognizing consensus splicing sites, 
non-snRNP splicing factors binding to splicing regulatory elements are also required to 
assemble the spliceosome. The two major non-snRNP splicing factor families are the 
serine/arginine-rich (SR) protein family and heterogeneous nuclear ribonucleoprotein 
(hnRNP) family. The SR proteins consist of one or two RNA recognition motifs (RRMs) 
and a carboxyl-terminal domain enriched with serine/arginine repeats (RS domain). The 
RRMs determine RNA binding specificity, whereas the RS domain mediates protein-
protein interactions (Caceres and Kornblihtt 2002). Conventionally, SR proteins 
recognize exonic splicing enhancers (ESEs) and recruit splicing machinery close to the 
exon/intron boundary and therefore enhance splicing; a minority of SR proteins act to 
inhibit splicing (Lin and Fu 2007). 
 
In contrast, hnRNPs were first described as a major group of chromatin-associated RNA-
binding proteins (Krecic and Swanson 1999). These proteins consist of at least one RNA 
binding motif such as an RNA recognition motif (RRM), hnRNP K homology (Defesche, 
Schuurman et al.) domain or a arginine/glycine-rich (RGG) box as well as auxiliary 
domains for protein-protein interactions (He and Smith 2009). HnRNPs recognize ESEs 
or exonic splicing silencers (Auclair, Busine et al.) to regulate splicing efficiency.  
 
Some splicing factors are extensively regulated by phosphorylation. For example, 
phosphorylation of SF2/ASF modulates its cellular localization (Caceres, Screaton et al. 
1998). In the cytosol, activated serine/threonine-protein kinase 1 (SRPK1) and SRPK2 
phosphorylate SF2/ASF (Wang, Lin et al. 1998), and thereby trigger SF2/ASF to 
translocate to the nucleus, where it can be further phosphorylated by CDC-like kinase 1 
(CLK1) and redistribute from nuclear speckles to splicing-active sites (Colwill, Pawson 
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et al. 1996). After splicing, SF2/ASF is dephosphorylated by protein phosphatase 1 
(PP1), which facilitates its nuclear export (Stamm 2008). Similarly, cellular localization 
of hnRNP A1 is also regulated by phosphorylation, but through phosphorylation of its 
transport partner, F-peptide (Allemand, Guil et al. 2005). In addition, phosphorylation 
may influence activity of splicing factors. For instance, phosphorylation of SF2/ASF 
increases its binding to U1 70-kDa snRNP and enhance splicing (Xiao and Manley 1997).  
 
Changes in RNA sequence that disrupt functional regulatory cis-acting elements can 
result in aberrant splicing and thereby cause human disease (reviewed in (Cooper, Wan et 
al. 2009; Tazi, Bakkour et al. 2009)). For example, mutations affecting RNA splicing are 
the most common cause of neurofibromatosis type 1 (NF1) (Ars, Serra et al. 2000) while 
mutations within and around exon 10 of microtubule-associated protein tau (MAPT) that 
disrupt exon 10 splicing regulation cause frontotemporal dementia with Parkinsonism 
linked to chromosome 17 (FTDP-17) (Liu and Gong 2008). These findings suggest that 
agents that alter splicing regulation can be a novel means of human disease therapy. 
 
Our lab previously identified a single nucleotide polymorphism (SNP), rs688, which 
modulates low-density lipoprotein receptor (LDLR) exon 12 splicing efficiency and is 
associated with higher cholesterol in pre-menopausal women (Zhu, Tucker et al. 2007) 
and with Alzheimer‟s disease in men (Zou, Gopalraj et al. 2008). I infer from the results 
that enhancing LDLR exon 12 splicing efficiency will lower cholesterol and reduce AD 
in relevant populations. However, the regulation of exon 12 splicing is still unclear. Here, 
I report that SRp20, SRp38 and hnRNP G decrease LDLR splicing in vitro. Moreover, 
SRp38 expression level is associated with LDLR splicing efficiency in vivo. I interpret 
these results as suggesting that SRp38 is a major modulator of LDLR splicing. 
 
Materials and Methods 
 
Cell culture 
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HepG2 (human hepatocellular carcinoma) cells were grown in Dulbecco‟s modified 
Eagle‟s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin⁄streptomycin at 37°C in a humidified 5% CO2-95% air atmosphere. 
 
Vectors 
LDLR minigenes containing exons 9-14 with rs688T or rs688C in pcDNA3.1, were 
previously described (Zhu, Tucker et al. 2007); the rs688T vector was derived from the 
rs688C by using site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit, 
Stratagene) according to the manufacturer‟s directions. Vectors encoding hnRNP F and 
hnRNP H, as well as their parent vector pcDNA4, were generous gifts from Dr. Paula 
Grabowski (University of Pittsburgh) (Han, Yeo et al. 2005). Vectors encoding the other 
splicing factors used here, as well as a pEGFP-C2 negative control vector encoding only 
EGFP were kindly provided by Dr. Stefan Stamm (University of Kentucky). These 
vectors, most of which encode the splicing factor as a fusion protein with EGFP, have 
been previously characterized (Screaton, Caceres et al. 1995; Novoyatleva, Heinrich et al. 
2008; Heinrich, Zhang et al. 2009). 
 
Evaluation of LDLR minigene splicing efficiency in vitro  
Splicing factor effects on LDLR splicing efficiency were evaluated by co-transfecting 
vectors encoding each splicing factor with the LDLR exon 9-14 or exon 12 minigene 
(rs688C or rs688T) into HepG2 cells. Splicing factor effects were considered relative to 
LDLR minigene co-transfected with either pEGFP or “empty” pcDNA4 (similar results 
were obtained with each negative control). Vectors were transfected by using FuGene 6 
transfection reagent as directed by the manufacturer (Roche Applied Sciences, 
Switzerland). Briefly, 1.5 x 10
5
 cells were seeded in a 6-well plate in 2 ml of medium 
without antibiotics one day before performing the transfection. The next day, 1 µg of 
LDLR minigene and 1 µg of splicing factor construct were mixed with 6 µl of FuGENE 
reagent in 94 µl of Opti-MEM (GIBCO) for 30 minutes and added to cell culture. 
Twenty-four hours later, transfection efficiency was evaluated by observing green 
fluorescence of EGFP-fused splicing factors by microscope (Nikon Diaphot 200, Japan). 
Then, total RNA was isolated (RNeasy Mini Kit, QIAGEN) and analyzed for LDLR 
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splicing patterns by reverse transcriptase-PCR (RT–PCR) as previously described (Zhu, 
Tucker et al. 2007). One µg of RNA was converted to cDNA (SuperScript III, Invitrogen) 
and sequences corresponding to LDLR minigene splice products were PCR amplified 
(Platinum Taq, Invitrogen). For the LDLR exon 9-14 minigene, PCR was performed with 
an LDLR exon 10 sense primer 
5‟
CATCGTGGTGGATCCTGTTC
3‟
 and, to obviate 
endogenous LDLR, a vector-specific antisense primer 
5‟
GGGATAGGCTTACCTTCGAA
3‟
. The PCR profiles consisted of initial denaturation 
at 94°C for 4 min, followed by cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s, 
and final extension at 72°C for 7 min. For the LDLR exon 12 minigene, PCR was 
performed with primers corresponding to the 5‟ and 3‟ -globin exons in pSPL3b, i.e., 
5‟
TCTCAGTCACCTGGACAACC
3‟
 and 
5‟
CCACACCAGCCACCACCTTCT
3‟
, 
respectively. The PCR profiles consisted of initial denaturation at 94°C for 4 min, 
followed by cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s, and final extension 
at 72°C for 7 min. The minimal number of PCR cycles necessary to discern products was 
performed, i.e. 23 cycles. PCR products were separated by polyacrylamide gel 
electrophoresis (PAGE) and visualized by SYBR-gold fluorescence on a fluorescence 
imager (Fuji FLA-2000). PCR product identities were determined by gel purification and 
direct sequencing (Davis Sequencing). The amount of full length and inefficiently spliced 
LDLR isoforms were quantified by fluorescence intensity. For each sample, fluorescence 
values were corrected for background and normalized for length differences among 
amplicons. Sample splicing efficiency was then quantified as the amount of FL LDLR 
PCR product containing exons 10-14 divided by the total LDLR PCR product for that 
sample. 
 
For experiments evaluating the dose-dependence of the splicing factors, 0.01, 0.1, or 1 g 
of vectors encoding the splicing factor (total amount made up to 1 g with “negative 
control” pcDNA4) was co-transfected with 1 g of LDLR minigene containing rs688C. 
Twenty-four hours after transfection, total RNA was collected and splicing efficiency 
was evaluated by RT-PCR as described above. 
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Effect of splicing factors on mutant LDLR minigene splicing was evaluated by co-
transfecting 1 g of vector encoding the splicing factor with 1 g of wild type (WT) or 
mutant (MT) LDLR minigenes. Twenty-four hours after transfection, total RNA was 
collected and splicing efficiency was evaluated by RT-PCR as described above. 
 
Western blot 
Twenty-four hours after transfection, HepG2 cells were washed with 1 ml of room 
temperature phosphate buffered saline (PBS) and lysed in 80 l of RIPA butter (50 mM 
Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) containing 
1X protease inhibitor cocktail (Roche Applied Science) for 30 minutes on ice with 
occasional rocking. A cell scraper was used to collect the cell lysate. Lysates were pooled 
from three wells for each sample and centrifuged at 10,000xg for 10 minutes at 4 C. Fifty 
l of protein extract was mixed with 10 l of 6X SDS sample loading buffer containing 
-mercaptoethanol, boiled for 5 minutes and subjected to electrophoresis on a 12% 
polyacrylamide gel. Proteins were transferred to nitrocellulose membranes (Bio-Rad). 
The blots were then blocked with 5% non-fat powdered milk in PBS for 1 hour at room 
temperature and probed overnight at 4 C with a mouse anti-GFP antibody (1:200 
dilution; Cat. No. 11814460001, Roche Applied Science) or with a mouse anti-Actin 
antibody (1:200 dilution; Cat. No. sc-8432, Santa Cruz Biotechnology) or with a rabbit 
anti-SRp38 antibody (0.5 g/ml; Cat. No. ARP41083_P050, Aviva Systems Biology). 
After washing with 0.1% Tween-20 in PBS four times for 5 minutes each, the blots were 
incubated with peroxidase-conjugated sheep anti-mouse antibody (1:1,000 dilution, 
Jackson ImmunoResearch) or peroxidase-conjugate goat anti-rabbit antibody (1:50,000 
dilution, Jackson ImmunoResearch) for 1 hour at room temperature. Bound peroxidase 
was visualized by using a SuperSignal West Pico kit (Pierce) and a molecular imager 
(ChemiDoc XRS System, Bio-Rad). 
 
Cell viability after cantharidin treatment 
HepG2 cells were grown with media containing 0, 0.7, 2, or 6 M of cantharidin for 24 
hours, and then stained with 5 µg/ml of calcein-AM (Molecular Probes, Invitrogen) and 
10 µg/ml of propidium iodide (PI) (Molecular Probes, Invitrogen) for 20 min at 37°C. 
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The fluorescence of calcein-AM and PI was observed by microscopy (Nikon Diaphot 
300, Japan). The number of viable and dead cells was counted in 4 different microscopic 
fields at 20X magnifications, and the ratio of viable cells to total cells was estimated. 
 
siRNA knockdown of SRp38 
Two siRNAs targeting SRp38 were predesigned by Integrated DNA Technologies 
(Varret, Rabes et al.) Inc. The sequences are 
5‟
ACAGUAGACCGACUGGAAGACCACG
3‟
 for siRNA 1 
(HSC.RNAI.N054016.10.8.2) and 
5‟
AGACUUGCGGCGUGAAUUUGGUCGT
3‟
 for 
siRNA 2
 
(HSC.RNAI.N054016.10.8.2). The two siRNAs sequences correspond to SRp38 
exons 5 and 2 respectively. Since SRp38 and SRp38-2 share the same exons 1-5, both 
SRp38 and SRp38-2 were targeted. A scrambled siRNA as a negative control (NC 
siRNA) and a positive control siRNA targeting hypoxanthine-guanine 
phosphoribosyltransferase (HPRT siRNA) were also purchased from IDT. One g of 
vector encoding SRp38 or LDLR exon 9-14 minigene was co-transfected with respective 
concentration of siRNAs (0.1, 1, 2 nM) by using Lipofectamine 2000 transfection reagent 
as directed by the manufacturer (Invitrogen). Briefly, 4 x 10
5
 cells were seeded in a 6-
well plate in 2 ml of medium without antibiotics one day before performing the 
transfection. The next day, respective siRNA concentrations in 250 µl of Opti-MEM 
were prepared and mixed with 2 µg of LDLR minigene. Ten µl of Lipofectamine 2000 in 
250 µl of Opti-MEM was prepared and added to the siRNA mixture. Solutions was 
incubated for 30 minutes and added to cell culture. Twenty-four hours later, total RNA 
was collected, and LDLR splicing efficiency was evaluated by RT-PCR as described 
above. SRp38 mRNA expression was quantified by real-time RT-qPCR. Total protein 
was also collected for SRp38 western blot. 
 
shRNA knockdown of SRp38  
Three shRNAs targeting SRp38 were purchased from Open Biosystems, Thermo 
Scientific (Cat. Number RHS4430-99290688, -98895307, -98911716). A non-silencing –
GIPZ shRNA vector was also purchased as a negative control (NC shRNA). HepG2 cells 
were first transfected with 2 g of respective shRNA vectors by using FuGene 6 
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transfection reagent as described above, and after two-days incubation, media was 
changed to selective media containing 3 g/mL of puromycin. After selection for 6 days, 
cells were transfected with 2 g of the LDLR exon 9-14 minigene by FuGene 6 reagent. 
Then, minigene splicing efficiency and SRp38 expression were quantified. Twenty-four 
hours later, total RNA or total protein was collected for analyses. 
 
Human tissues 
Human liver samples were obtained from the Brain and Tissue Bank for Developmental 
Disorders (Baltimore, MD) and have been previously described (Zhu, Tucker et al. 2007). 
The samples were from deceased individuals with an average age at death for women of 
28 ± 9 years (mean ± SD, range of 15−44, n = 15) and for men of 27 ± 10 (range 13−46, 
n = 20). The average post-mortem interval (PMI) for women was 13 ± 5 hours (mean ± 
SD, range 4−19, n = 15) while the PMI for men was 10 ± 3 hours (range 3−14, n = 20).  
 
Human anterior cingulate brain specimens were generously provided by the Sanders-
Brown Alzheimer‟s Disease Center Neuropathology Core and have also been described 
elsewhere (Zou, Gopalraj et al. 2008). The samples were from deceased individuals with 
an average age at death for females of 82 ± 7 years (mean ± SD, n = 31) and for males of 
82 ± 8 (n = 28). The average postmortem interval (PMI) for females and males was 3.0 ± 
0.8 h (mean ± SD, n = 31) and 3.1 ± 0.8 h (n = 28), respectively.  
 
Evaluation of LDLR splicing efficiency in vivo 
Total RNA was prepared from the human liver and brain specimens and converted to 
cDNA in 1 g aliquots with random hexamers and reverse transcriptase (SuperScript III, 
Invitrogen) (Chomczynski and Sacchi 1987). The LDLR splicing efficiency in brain 
specimens was evaluated by RT-PCR as we previously described for the liver specimens 
(Zhu, Tucker et al. 2007). Briefly, LDLR exon 10 sense primer 
5‟
CCTGGCCAGCAGCATGCCGTC
3‟
 and exon 14 antisense primer 
5‟
CATCGTGGTGGATCCTGTTC
3‟
 were used to PCR-amplify (Platinum Taq, 
Invitrogen) brain cDNAs corresponding to LDLR exons 10−14, as well as isoforms 
lacking exons 11 and/or 12. PCR profiles consisted of preincubation at 94°C for 4 min, 
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followed by cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s, and final extension 
at 72°C for 7 min. The minimal number of PCR cycles necessary to discern products was 
performed, e.g., 30 cycles. PCR products were separated by PAGE and quantified as 
described above. 
 
Real-time RT-qPCR for splicing factor expression in vivo 
The expression level of SRp20, SRp38 and hnRNP G in the liver and brain specimens 
was quantified by real-time RT-qPCR. The 20 l RT-qPCR mixture containing 
approximately 20 ng of liver or brain cDNA, 1 M of each primer and 1× SYBR Green 
PCR Master Mix (Ambion) was subjected to RT-qPCR (MJ Research PTC-200 with 
Chromo4 detector). PCR profiles consisted of preincubation at 95°C for 10 min, followed 
by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Specificity of the 
reactions was evaluated by showing a single PCR product by gel electrophoresis and by 
performing a melting curve analysis after the PCR amplification. The copy numbers of 
PCR product in each sample were determined relative to standard curves that were 
amplified in parallel and were based upon standardized amounts of purified PCR 
products. The following mRNAs and primers were evaluated: SRp20: 
5‟
CGGCTTTGCTTTTGTTGAAT
3‟
 and 
5‟
TCACCATTCGACAGTTCCAC
3‟
; SRp38: 
5‟
ATTTCTACACTCGCCGTCCA
3‟
 and 
5‟
CCGTCCACAAATCCACTTTC
3‟
; hnRNP G: 
5‟
GTAGCAGTGGAATGGGAGGA
3‟
 and 
5‟
CCATCATCTCTTGGGGACAA
3‟
; 
ribosomal protein L13A (RPL): 
5‟
CATCTCCTTCTCGGCATCA
3‟
 and 
5‟
AACCCTGTTGTCAATGCCTC
3‟
; hypoxanthine-guanine phosphoribosyltransferase 
(HPRT): 
5‟
GACCAGTCAACAGGGGACAT
3‟
 and 
5‟
AACACTTCGTGGGGTCCTTTTC
3‟
. The geometric mean of RPL and HPRT was 
used to normalize splicing factor expression among the samples (Vandesompele, De 
Preter et al. 2002). All RT-qPCR assays were repeated twice. 
 
Statistical analysis 
The effect of splicing factor and phosphorylation-related protein ectopic expression on 
LDLR minigene splicing efficiency was analyzed by using analysis of variance 
(ANOVA) and a post-hoc Scheffe test (SPSS software, v 17, SPSS Inc., Chicago, IL). 
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The effect of cantharidin treatment on DLLR minigene splicing was also analyzed by 
ANOVA and a post-hot Scheffe test (SPSS). The correlation between LDLR splicing 
efficiency and splicing factor expression was analyzed by using a linear regression model 
(SPSS). 
 
Results 
 
Screening of SR protein family members for modulating LDLR splicing 
To identify splicing factors that may modulate LDLR splicing efficiency, I quantified the 
effects of eleven widely studied SR protein family members on splicing of the LDLR 
exon 9-14 minigene (Zhu, Tucker et al. 2007). I co-transfected the LDLR minigenes 
containing either rs688C or rs688T alleles with vectors encoding candidate SR proteins 
into HepG2 cells. Since some of the splicing factors were encoded as EGFP fusion 
proteins, e.g., ASF, SRp38, and SRp38-2, I confirmed their ectopic expression by 
fluorescence microscopy (Figure 3.1). Splicing efficiency was quantified 24 hours later 
by RT-PCR. The proportion of full length (FL) LDLR transcript was consistently less 
with the rs688T allele than the rs688C allele (Figure 3.2), reproducing our earlier 
observation of a SNP-induced effect on splicing (Zhu, Tucker et al. 2007). None of the 
SR proteins showed a SNP-dependent effect. Rather, many of the SR proteins reduced 
LDLR minigene splicing efficiency, with SRp20, SRp38, and SRp38-2 showing the 
largest changes (Figure 3.2B). SRp20 reduced FL LDLR by specifically increasing an 
LDLR transcript that skipped exon 11, i.e., Delta 11 LDLR (p < 0.001) (Figure 3.2C). 
SRp38 acted similarly to increase Delta 11 (Figure 3.2C) while SRp38-2 acted primarily 
by increasing the LDLR isoform that lacked both exons 11 and 12 (Figure 3.2E). 
Interestingly, SRp38 and SRp38-2 are alternatively spliced isoforms from the same gene; 
SRp38 includes one RNA recognition motif (RRM) and three RS domains while SRp38-
2 has the same RRM but only one RS domain (Komatsu, Kominami et al. 1999).  
 
Screening of hnRNP family members for modulating LDLR splicing 
HnRNPs are also critical splicing regulatory proteins. Therefore, I also screened ten well-
characterized hnRNP family members for their effects on LDLR splicing. I found that 
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hnRNP G and hnRNP G-T showed the largest effects (Figure 3.3B), decreasing the 
inclusion of exons 11 and 12 in the final LDLR mRNA product, regardless of which 
rs688 allele was present (p < 0.001; Figure 3.3E). Since hnRNP G has been reported to 
influence splicing in an RRM-independent fashion (Heinrich, Zhang et al. 2009), I further 
evaluated the effects of a truncated hnRNP G form that lacks the RRM domain. The 
result was identical to hnRNP G (Figure 3.3B-E); I interpret these results as indicating 
that hnRNP G may modulate LDLR splicing by acting as a scaffold protein without 
binding to LDLR mRNA.  
 
Dose-dependent effect of splicing factors 
Overall, the in vitro screening identified SRp20, SRp38, SRp38-2, hnRNP G and hnRNP 
G-T as candidates for modulating LDLR splicing in human tissues. Since the expression 
of hnRNP G-T is restricted to testis (Elliott, Venables et al. 2000), I focused on the first 
four splicing factors in subsequent studies. To evaluate whether these splicing factors 
repressed LDLR minigene splicing in a dose-dependent manner, three doses (0.01, 0.1, 
and 1 g) of the vectors encoding the splicing factors were co-transfected with 1 g of 
LDLR minigene. Since three of the four splicing factors were encoded as EGFP fusion 
proteins, I confirmed that expression was indeed dose-dependent by using anti-GFP 
Western blots (Figure 3.4A). When I analyzed LDLR minigene splicing by RT-PCR, I 
found that as the dose of splicing factor increased, the splicing factor effects on LDLR 
splicing increased as well (Figure 3.4B-F). SRp20 and SRp38 acted mostly by increasing 
Delta 11, while SRp38-2 and hnRNP G increased Delta 11+12, consistent with the results 
described in Figures 3.2 and 3.3. Hence, these results confirm that these splicing factors 
modulate LDLR splicing in a dose-dependent manner. 
 
Effect of splicing factors on LDLR exon 12 minigene 
To evaluate whether these splicing factors also modulate splicing efficiency of LDLR 
exon 12 minigene, I co-transfected vectors encoding these splicing factors with the 
LDLR single exon minigene containing rs688C allele. When the vector encoding SRp20 
was co-transfected, the expression of LDLR minigene transcripts was very low 
precluding their quantitation; the mechanism for this observation is unclear. In contrast, 
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SRp38, SRp38-2 and hnRNP G co-transfections did not decrease LDLR transcript 
expression, but all increased the percentage of Delta 12 LDLR (Figure 3.5B). 
Interestingly, when the LDLR exon 9-14 minigene was transfected, SRp38-2 showed 
stronger effect on decreasing minigene splicing than SRp38 (Figure 3.2 and 3.4); 
however, when the single exon minigene was transfected, SRp38 had bigger effect on 
decreasing exon 12 splicing (Figure 3.5). HnRNP G and hnRNP G lacking the RRM had 
similar effects on single exon minigene splicing, indicating that hnRNP G regulated exon 
12 splicing without itself binding to LDLR pre-mRNA. I interpret the results as 
suggesting that these splicing factors may interact with regulatory cis-elements within 
exon 12 either directly or indirectly binding to the RNA.   
 
Effect of splicing factor on mutant LDLR minigenes 
As described in Chapter Two, I have identified two functional ESE regions defined by 
MT6 and MT7 that are critical to LDLR exon 12 splicing. To understand whether these 
splicing factors interact with the two functional ESE regions, I co-transfected vectors 
encoding relevant splicing factors with either wild type (WT) or mutant (MT) LDLR 
exon 9-14 minigene, and quantified splicing efficiency by RT-PCR. A vector encoding 
EGFP was co-transfected as a negative control for splicing factor ectopic expression. 
Compare to WT, when MTs were co-transfected with the vector encoding EGFP, the 
splicing efficiency decreased (Figure 3.6B). The MTs increased primarily the percentage 
of Delta 12 LDLR and some Delta 11+12 (Figure 3.6D-E). When MTs were co-
transfected with relevant splicing factors, they decreased splicing efficiency distinctly; 
SRp20 and SRp38 still increased Delta 11 (Figure 3.6C), and SRp38-2 and hnRNP G 
increased Delta 11+12 (Figure 3.6E). If the splicing factors required binding to the two 
ESE regions to function, they would lose their effects on splicing when co-transfected 
with ESE mutants. Therefore, I interpreted the results as that these splicing factors didn‟t 
interact with the two critical ESE regions within LDLR exon 12. Instead, they influence 
LDLR splicing by binding to other regulatory elements. 
 
SR protein phosphorylation and LDLR splicing 
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Some splicing factors are regulated by phosphorylation. For example, SRp20 is 
modulated by phosphorylation (Saeki, Yasugi et al. 2005; Sen, Talukdar et al. 2009); 
SRp38 is activated by dephosphorylation by PP1 (Shi and Manley 2007). To gain more 
insight, I decided to evaluate whether phosphorylation status influences LDLR splicing. I 
first evaluated effect of cantharidin, an inhibitor of PP1 and PP2A, on LDLR splicing. 
Since cantharidin is known as a toxic compound, I checked HepG2 cell viability by using 
calcein AM and PI double staining after cantharidin treatment for 24 hours. At the 
highest tested cantharidin concentration of 6 M, I didn‟t observe significant cell death 
although most cells assumed a round morphology (Figure 3.7). The percentage of viable 
cells slightly decreased from 99.5 ± 0.5% to 96.7 ± 1.1% with 6 M cantharidin 
treatment (Figure 3.8A). When I quantified LDLR exon 9-14 minigene splicing after 
cantharidin treatments, I found that 6 M of cantharidin significantly decreased LDLR 
splicing efficiency (Figure 3.8B).  
 
To further evaluate the effect of splicing-related kinase and phosphatase on LDLR 
splicing, I co-transfected the LDLR exon 9-14 minigenes containing either rs688C or 
rs688T alleles with vectors encoding splicing-related kinase and phosphatase into HepG2 
cells. Consistent with the results observed from cantharidin treatment (Figure 3.8B), 
nuclear inhibitor of PP1 (NIPP1) decreased the splicing efficiency as well (Figure 3.9B). 
While SRPK1 had no significant effect on LDLR minigene splicing, CLK2 increased the 
percentage of the Delta 11+12 LDLR (Figure 3.9E). Surprisingly, ectopic expression of 
PP1 also decreased the splicing efficiency by increasing the Delta 11+12 LDLR (Figure 
3.9E). I interpreted the results as suggesting that the LDLR splicing is modulated by 
multiple splicing proteins, and the phosphorylation status of these proteins may influence 
LDLR splicing. 
 
Knockdown of SRp38 expression 
To confirm that the splicing factors modulate LDLR splicing, I proceeded to evaluate 
changes in splicing efficiency after silencing expression of the splicing factor. I first used 
small interfering RNA (siRNA) to decrease SRp38 expression. When the siRNAs were 
co-transfected with a vector encoding SRp38, after 48 hours, I observed that siRNA 1 had 
 53 
a clear effect on reducing the ectopic SRp38 expression (Figure 3.10). When I co-
transfected the siRNAs with the LDLR exon 9-14 minigene, the siRNA 1 decreased 
endogenous SRp38 mRNA level to about 40% (Figure 3.11A). However, the siRNAs 
didn‟t reduce endogenous SRp38 protein level successfully, and hence, no change in 
LDLR minigene splicing (Figure 3.12).  
 
Considering that the difficulty of decreasing SRp38 protein level by siRNA may be due 
to stable protein expression, I then tried using short hairpin RNA (shRNA) to reduce 
SRp38 expression. NC shRNA or shRNAs targeting SRp38 (shRNA 1-3) were 
transfected into HepG2 cells and the transfected cells were selected by puromycin for 6 
days. Then the LDLR exon 9-14 minigene was transfected, and SRp38 expression and 
minigene splicing were evaluated. The results were similar to what I observed while 
using siRNA to decrease SRp38. The shRNA 3 had the strongest effect on decreasing 
SRp38 mRNA expression to about 50% (Figure 3.12A). However, I did not detect a 
reduction on SRp38 proteins level or LDLR splicing efficiency (Figure 3.12B). I attribute 
that lack of change in LDLR splicing efficiency to the lack of siRNA or shRNA effect on 
SRp38 proteins levels.  
  
Correlation between splicing factor expression and LDLR splicing in vivo 
To investigate whether these splicing factors are associated with LDLR splicing 
efficiency in vivo in a dose-dependent fashion, I quantified SRp20, SRp38, and hnRNP G 
expression as well as LDLR splicing in 59 human brain and 35 human liver specimens. 
Expression of the splicing factors was quantified by RT-qPCR; SRp38 and SRp38-2 were 
amplified by common primers. LDLR splicing efficiency was evaluated by RT-PCR with 
primer sequences corresponding to LDLR exon 10 and exon 14. Although others had 
reported sex-dependent differences in SRp20 expression and our lab had seen a sex-
dependent difference in LDLR splicing in vivo previously (Zhu, Tucker et al. 2007; Zou, 
Gopalraj et al. 2008), I did not discern any sex-dependent differences in the expression of 
SRp20, SRp38, or hnRNP G in brain or liver (Figure 3.13; Table 1). I proceeded to 
evaluate the correlation between splicing factor expression and LDLR splicing by using 
linear regression models that included each of the splicing factors as well as rs688 and 
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sex. I found that SRp38 expression correlated significantly with LDLR splicing in both 
the brain (p < 0.001, observed power = 0.999) and liver (p = 0.003, observed power = 
0.890). In contrast, SRp20 and hnRNP G expression was not significantly associated with 
LDLR splicing. Interestingly, the inclusion of both SPp38 expression and rs688 genotype 
in the model of LDLR splicing tended to reduce the association of rs688 with LDLR 
splicing, i.e., the association of rs688 with splicing efficiency in the liver remained 
significant (p = 0.040, observed power = 0.622) while the association of rs688 with 
splicing in the brain showed a strong trend (p = 0.062, power = 0.544). Consistent with 
our finding that SRp38 acted similarly upon the rs688C and rs688T LDLR minigenes, the 
interaction between SRp38 expression and rs688 genotype was not significant (p = 
0.138). Overall, increased SRp38 expression is associated significantly with decreased 
efficiency of LDLR splicing while rs688 genotype is associated significantly with LDLR 
splicing in the liver and trends with LDLR splicing in the brain. 
 
Discussion 
 
In this study, I identified several splicing factors that influence LDLR minigene splicing 
in transfected cells. Two of the factors, SRp20 and SRp38, increased Delta 11 LDLR 
while two other factors, SRp38-2 and hnRNP G, increased Delta 11+12 LDLR. A 
comparison of splicing factor expression and LDLR splicing efficiency in human brain 
and liver specimens established that SRp38 expression correlated with LDLR splicing 
efficiency. Overall, I interpret our results as suggesting that SRp38 modulates LDLR 
splicing in vivo. Since the association between SRp38 and LDLR splicing is more robust 
than that between rs688 and LDLR splicing, and rs688 itself is associated with 
cholesterol and AD (Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 2008), I propose that 
SRp38 may also emerge as a modulator of cholesterol homeostasis and AD risk. 
 
The critical nature of LDLR to cholesterol homeostasis is well established in that the loss 
of a single LDLR allele causes familial hypercholesterolemia (Hobbs, Brown et al. 1992). 
In addition, LDLR is a receptor for apoE in the brain (Fryer, Demattos et al. 2005; Cao, 
Fukuchi et al. 2006). Since alleles of apoE are the major AD genetic risk factors, factors 
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that modulate LDLR expression or splicing represent potential modulators of AD risk. 
Consistent with this possibility, a previous work demonstrated that rs688, a SNP within 
LDLR exon 12, modulates exon 12 splicing, and is associated with AD in at least some 
case-control series (Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 2008). The LDLR 
isoforms lacking exon 11 and/or 12 are predicted to encode a truncated LDLR that 
contains the ligand binding domain but lacks the transmembrane domain. Therefore, the 
truncated LDLR may act in a dominant negative fashion to interfere with normal LDLR 
function (Zhu, Tucker et al. 2007). Since these LDLR isoforms encode non-functional 
LDLR proteins, further work is necessary to elucidate the regulation of LDLR splicing. 
 
Several observations support the possibility that SRp38 is involved in LDLR splicing. 
First, each of the two SRp38 isoforms modulated LDLR minigene splicing in vitro. 
Second, the SRp38 isoforms acted in a dose-dependent manner to alter LDLR splicing in 
vitro. Third, SRp38 overall expression correlated with LDLR splicing efficiency in the 
brain and liver in vivo. Although the minigene co-transfection studies evaluated SRp38 
and SRp38-2 separately, my efforts to distinguish these SRp38 isoforms in the qPCR 
studies were unsuccessful. SRp38 is encoded by six exons and includes one RRM and 
three RS domains while SRp38-2 shares the same first five exons but uses an alternative 
exon 6. Hence, for my qPCR studies, I used primers which corresponded to exons 2 and 3 
and amplified both SRp38 and SRp38-2. Overall, SRp38 and SRp38-2 share a common 
RRM domain and RS domain but differ in that SRp38 has two additional RS domains 
(Komatsu, Kominami et al. 1999). Since RRM domains are responsible for protein-RNA 
interaction, SRp38 and SRp38-2 may recognize the same RNA sequence but recruit 
different splicing factors. This may account for the actions of SRp38 and SRp38-2 in the 
in vitro minigene studies, i.e., SRp38 and SRp38-2 acted similarly to increase Delta 
11+12 LDLR while only SRp38-2 also increased Delta 11 LDLR. Since I did not detect 
significant levels of Delta 11 LDLR in our in vivo studies, other factors may suppress 
Delta 11 LDLR in vivo.  
 
To further confirm that SRp38 proteins are critical modulators of LDLR splicing, I tried 
using siRNA and shRNA to inhibit SRp38 expression and evaluated effects on LDLR 
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splicing. However, the RNA interference (RNAi) methods were only able to decrease 
SRp38 mRNA expression by 40-50% with no reduction in protein level. I attribute the 
observation of no change in LDLR splicing to the lack of effect on SRp38 protein level. 
The difficulty of decreasing SRp38 expression by RNAi is possibly because first, SR 
proteins seem to be very stable, and second, SRp38 has at least three pseudogenes 
(Clinton, Chansky et al. 2002). On the other hand, SRp38 has been reported regulated by 
phosphorylation. Dephosphorylated SRp38 is known as a general splicing repressor 
during M phase of cell cycle (Shin and Manley 2002) and during heat shock (Shin, Feng 
et al. 2004). Shi and Manley have shown that SRp38 is dephosphorylated by PP1 and 14-
3-3 protects SRp38 from dephosphorylation (Shi and Manley 2007). Therefore, to block 
SRp38 activity through regulation of dephosphorylation and then evaluate the effect on 
LDLR splicing would be interesting. 
 
Since rs688 previously has been found to modulate LDLR exon 11-12 splicing in a sex-
dependent fashion, the positive SRp20 results in my screening were interesting because 
SRp20 expression has been reported to show sex-dependent expression differences. In 
particular, Antunes-Martins et. al. found that hippocampal SRp20 mRNA expression was 
higher in male mice than female mice both at basal state and following its upregulation 
by memory training, i.e., the spatial version of the Morris water maze and background 
contextual fear conditioning (Antunes-Martins, Mizuno et al. 2007). However, I did not 
detect differences in SRp20 expression between male and female humans. This may 
reflect that I compared expression in human anterior cingulate while Antunes-Martins et. 
al compared murine hippocampus. Characterization of murine SRp20 promoter revealed 
that SRp20 expression is probably regulated in a cell-specific fashion (Jumaa, Guenet et 
al. 1997). Therefore, it would be interesting to investigate SRp20 expression in human 
hippocampus. 
 
Another interesting candidate regarding sex-dependent splicing is hnRNP G and its 
paralog, RBMY, which shares 57% sequence homology with hnRNP G. In humans, 
hnRNP G is encoded by the RBMX gene which is located on the X chromosome while 
RBMY is encoded by RBMY, an RBMX paralog on the Y chromosome (Ma, Inglis et al. 
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1993). Hence, both males and females express RBMX while only males express RBMY, 
suggesting that RBMY could alter LDLR splicing in a sex-dependent fashion. Here I 
observed that hnRNP G and RBMY both decreased LDLR splicing with RBMY having a 
weaker effect (Figure 2). However, RBMY, like hnRNP G-T, is only expressed in testis 
where it is critical for spermatagenesis (Ma, Inglis et al. 1993) Therefore, the RBMY 
modulation of LDLR splicing in vitro may be physiologically relevant only in testis. In 
contrast, hnRNP G is ubiquitously expressed. I found that hnRNP G robustly decreased 
LDLR minigene splicing in an RRM-independent fashion, indicating that hnRNP G may 
interact with other splicing factor(s) and function as a scaffold protein to modulate LDLR 
splicing. Since HnRNP G has been reported to interact with Tra2-ß1, (Hofmann and 
Wirth 2002; Nasim, Chernova et al. 2003), I considered the possibility that Tra2ß1 could 
mediate hnRNP G effects. However, Tra2- 1 overexpression did not cause a significant 
change in LDLR minigene splicing (Figure 1), suggesting that hnRNP G influenced 
LDLR splicing via other mechanisms in vitro.  
 
In summary, I identified several splicing factors which modulate LDLR splicing in vitro 
with SRp20, SRp38, SRp38-2 and hnRNP G having the strongest effects. I then found 
that increased SRp38 mRNA expression correlated with decreased LDLR splicing 
efficiency in the human brain and liver. Overall, I interpret the results as suggesting that 
SRp38 may be critical in the regulation of LDLR splicing. Since other factors that 
modulate LDLR splicing, e.g., rs688, have been associated with cholesterol and 
Alzheimer‟s disease (Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 2008), I propose that 
SRp38 as a candidate for modulating cholesterol homeostasis and AD risk. 
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Figure 3.1 Expression of transfected SR proteins 
HepG2 cells co-transfected with vectors encoding EGFP-fused SR proteins were 
confirmed by observing green fluorescence under microscope at 20X magnification. 
Transfection efficiency of the SR proteins ranged from 20-30% by counting the green 
cells relative to total cells. Representative results from SRp38 and SRp38-2 transfection 
were shown. 
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Figure 3.2 SR protein family effects on LDLR minigene splicing in vitro 
HepG2 cells were co-transfected with vectors encoding different SR proteins and LDLR 
rs688C or rs688T in an exon 9-14 minigene. The effects of the SR proteins and rs688 
allele on LDLR minigene splicing are shown as representative gel images (A) and 
quantitative results (B-E, mean ± SD, n = 3, * and + reflect p < 0.01 when compared to 
rs688T and rs688C minigenes, respectively, co-transfected with the negative control 
pEGFP vector). The faint PCR products observed between FL and Delta 11, and between 
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Delta 12 and Delta 11+12 represent non-physiologic LDLR splice variants, i.e., FL 
LDLR lacking the first 74 bp of exon 14, and a Delta 13 LDLR isoform, respectively. 
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Figure 3.3 HnRNP family member effects on LDLR minigene splicing in vitro 
HepG2 cells were co-transfected with vectors encoding different hnRNP family members 
and LDLR rs688C or rs688T-containing minigenes. The effects of the hnRNPs and rs688 
allele on LDLR minigene splicing are shown as representative gel images (A) and 
quantitative results (B-E, mean ± SD, n = 3, * and + reflect p < 0.01 when compared to 
rs688T and rs688C minigenes co-transfected with the negative control pEGFP vector).  
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Figure 3.4 Splicing factors show dose-dependent effects on LDLR splicing 
The indicated amounts of vectors encoding splicing factors were co-transfected with 1 g 
of the vector encoding the rs688C allele LDLR minigene. The total amount of non-LDLR 
vector in the transfections was held constant at 1 g by adding “negative control” 
pcDNA4 vector. The dose-dependent overexpression of SRp38, SRp38-2 and hnRNP G 
was confirmed by Western blots (A). Dose dependent effects on LDLR minigene splicing 
efficiency are shown as a representative image (B) and overall quantitation (C-F, mean ± 
SD, n = 3).  
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Figure 3.5 Effect of splicing factors on LDLR exon 12 minigene splicing 
The LDLR exon 12 minigene containing rs688C allele was co-transfected with vectors 
encoding respective splicing factors. The effects of the splicing factors on LDLR single 
exon minigene splicing are shown as a representative gel image (A) and quantitative 
results (B, mean ± SD, n = 3, * reflects p < 0.01 when compared to rs688C minigenes co-
transfected with the negative control pEGFP vector). 
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Figure 3.6 Effects of splicing factors on mutant LDLR minigene splicing 
Equal amount of wild type (WT) or mutant (MT) LDLR exon 9-14 minigene was co-
transfected with vectors encoding respective splicing factors into HepG2 cells. Splicing 
factor effects on LDLR minigene splicing efficiency are shown as a representative gel 
image (A) and overall quantitation (B-E, mean ± SD, n = 3).  
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Figure 3.7 Evaluation of HepG2 cell viability after cantharidin treatment 
After treatment of respective concentration of cantharidin for 24 hours, cell viability was 
evaluated by calcein-AM and PI double staining. Calcein-AM permeates cell membrane 
and after converted to calcein by esterase in a viable cell, it emits green fluorescence. 
Hence, calcein-AM stains viable cells. In contrast, PI is impermeable to cell membrane, 
and thus stains dead cells. PI binds to DNA and emits red fluorescence. Images shown 
were at 20X magnification.  
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Figure 3.8 Cantharidin effect on cell viability and LDLR minigene splicing 
Cell viability after cantharidin treatment was estimated by the ratio of viable cells to total 
cells, and quantitative results were shown (A). No significant increase in cell death was 
detected after 24-hours incubation with 6 M cantharidin. Quantitative results of 
cantharidin effect on the LDLR splicing were shown (B, mean ± SD, n = 3, * and + 
reflect p < 0.01 when compared to rs688T and rs688C minigenes without cantharidin 
treatment). 
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Figure 3.9 Effect of kinases and PP1 on LDLR minigene splicing 
HepG2 cells were co-transfected with vectors encoding kinases and PP1 and LDLR 
rs688C or rs688T-containing minigenes. The effects of phosphorylation-related protein 
ectopic expression on LDLR minigene splicing are shown as a representative gel image 
from C allele co-transfection (A) and quantitative results (B-E, mean ± SD, n = 3, * and + 
reflect p < 0.01 when compared to rs688T and rs688C minigenes co-transfected with the 
negative control pEGFP vector).  
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Figure 3.10 siRNA knockdown of ectopic SRp38 expression   
 69 
A negative control scrambled siRNAs (NC siRNA) or 2 siRNAs targeting SRp38 were 
co-transfected with a vector encoding SRp38. Since the vector expresses an EGFP-fused 
SRp38, the expression of the ectopic SRp38 was evaluated by observing green 
fluorescence under microscopy. While siRNA 2 had no significant effect, siRNA 1 
significantly decreased the green fluorescence, indicating reduction of the ectopic SRp38 
expression. Images shown were at 20X magnification.  
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Figure 3.11 siRNA decreased mRNA expression 
NC siRNA or 2 siRNA targeting SRp38 were transfected into HepG2 cells, as well as a 
positive control siRNA targeting HPRT (HPRT siRNA), and then RNA expression was 
quantified by real-time RT-qPCR. While 10 nM of HPRT siRNA efficiently decreased 
HPRT mRNA expression to 20% (A, mean ± SD, n = 3), the strongest effect on reducing 
SRp38 expression is about 40% by 30 nM of siRNA 1 (B, mean ± SD, n = 3). Similar 
knockdown result was observed when higher concentration of siRNA (100 nM) was 
transfected. SRp38 expression was normalized to the geometric mean of RPL and HPRT 
as described (Vandesompele, De Preter et al. 2002), but for the positive control siRNA 
targeting HPRT, the HPRT expression was only normalized to RPL expression. 
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Figure 3.12 Effect of siRNAs on endogenous SRp38 expression and LDLR minigene 
splicing 
SRp38 protein expression was evaluated by Western blot after siRNA treatment, and no 
significant change was detected (A). Western blot for actin was also performed as an 
internal control. Protein ladder is labeled on the left of the representative image. The 
lower band of SRp38 is possibly dephosphorylated SRp38. Quantitative results for effect 
of the siRNAs on LDLR minigene splicing are shown (B, mean ± SD, n = 3).  
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Figure 3.13 Effect of shRNAs on SRp38 expression and LDLR minigene splicing 
The effects of SRp38 shRNAs on SRp38 mRNA expression (A) and LDLR minigene 
splicing (B) are shown as quantitative results (mean ± SD, n = 3). While shRNA 3 
showed the strongest effect on decreasing SRp38 mRNA expression to 50%, no 
significant change in LDLR minigene splicing.  
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Figure 3.14 Splicing factor expression in human brain and liver 
Splicing factor expression was quantified by real-time RT-qPCR in 59 human brain (A) 
and 35 liver specimens (B). Expression was normalized to the geometric mean of RPL 
and HPRT as described (Vandesompele, De Preter et al. 2002). Each black dot reflects 
one specimen. The 59 brain specimens include 31 males and 28 females, and the liver 
specimens contain 20 males and 15 females.  
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Human Brains   Human Livers  
Female  Male  P  
 
Female  Male  P  
(n = 28) (n = 31) Value (n = 15) (n = 20) Value  
SRp20 0.883 ± 0.399 0.824 ± 0.438 0.59  3.552 ± 1.620 3.830 ± 2.176 0.68  
SRp38 0.958 ± 0.625 0.847 ± 0.538 0.47  6.264 ± 1.997 6.151 ± 2.241 0.88 
 
hnRNP G 0.539 ± 0.262 0.476 ± 0.241 0.35  1.795 ± 0.844 2.048 ± 1.304 0.52 
 
 
Table 3.1 Splicing factor expression in human brain and liver 
These results reflect the mean ± SD for the expression of the indicated splicing factors. 
Expression was normalized to the geometric mean of RPL and HPRT as described 
(Vandesompele, De Preter et al. 2002). 
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Figure 3.15 SRp38 and rs688 are associated with LDLR splicing efficiency 
The relationship between LDLR splicing efficiency, SRp38 expression and rs688 
genotype are shown. As expression level of SRp38 increased, the splicing efficiency of 
LDLR decreased. (A) In brain, specimens included 16 rs688C/C, 18 rs688C/T, and 19 
rs688T/T. The r
2
 for the model is 0.309. (B) In liver, specimens included 8 rs688C/C, 16 
rs688C/T and 15 rs688T/T. The r
2
 for the model is 0.213. The solid lines represent fit 
lines and the dashed lines represent 95% confidence interval. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Copyright © I-Fang Ling 2009 
 76 
CHAPTER FOUR 
DISCUSSION AND CONCLUSIONS 
 
A genetic polymorphism located in a splicing regulatory element can influence gene 
splicing, resulting in aberrant protein expression or function and causing diseases. 
Understanding splicing regulation can lead to discovery of novel molecular mechanisms 
underlying disease development, and possibly new therapeutic targets. Our lab has 
previously identified a functional SNP, rs688, that modulates LDLR splicing efficiency, 
i.e., the minor T allele decreases LDLR exon 12 splicing efficiency compared to the 
major C allele (Zhu, Tucker et al. 2007). Furthermore, rs688 is associated with higher 
cholesterol in pre-menopausal women (Zhu, Tucker et al. 2007) and with Alzheimer‟s 
disease in men (Zou, Gopalraj et al. 2008). However, the mechanism of rs688 modulating 
LDLR exon 12 splicing and the regulation of LDLR splicing are still unclear. To gain 
more insight, I aimed to investigate the regulation of LDLR splicing efficiency in this 
study: first, to identify functional ESEs within LDLR exon 12, and second, to identify 
splicing factors that modulate LDLR splicing efficiency. 
 
Findings 
 
To identify functional ESEs within LDLR exon 12, I first identified nine conserved 
putative ESE regions by using in silico methods, and then mutated these regions to 
neutralize their affinity to splicing factors. Two ESE regions separated by only 11 bp 
were confirmed as critical to LDLR exon 12 splicing, and interestingly, rs688 is located 
in between these regions. The results confirmed that rs688 is located close to important 
splicing regulatory elements, and hence, modulates LDLR splicing efficiency.  
 
To identify splicing factors that modulate LDLR splicing efficiency, I screened splicing 
factors from both the SR protein family and the hnRNP family. Several splicing factors 
showed effects on LDLR minigene splicing with SRp20, SRp38, SRp38-2 and hnRNP G 
having the strongest effects. While SRp20, and SRp38 specifically increased the LDLR 
transcript lacking exon 11, SRp38-2 and hnRNP G increased the transcript lacking exons 
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11 and 12. All four splicing factors repressed LDLR splicing in a dose-dependent 
manner. Interestingly, hnRNP G did not require its RRM to affect LDLR splicing, 
indicating that hnRNP G may interact with other splicing factor that binds to LDLR pre-
mRNA.  
 
Co-transfection with vectors encoding kinases or PP1 revealed that LDLR splicing is also 
regulated by phosphorylation status. While SRPK1 had no significant effect on LDLR 
minigene splicing, CLK2 increased the percentage of the Delta 11+12 LDLR. 
Surprisingly, ectopic expression of PP1 also altered splicing efficiency by increasing the 
Delta 11+12 LDLR. I interpreted the results as suggesting that LDLR splicing is complex 
and regulated by multiple splicing factors. The phosphorylation status of these proteins 
affects LDLR splicing. 
 
These splicing factors not only affected splicing efficiency of the LDLR exon 9-14 
minigene, but also the exon 12 only minigene, indicating that they may interact with the 
functional ESE regions identified within LDLR exon 12. However, the effects of the ESE 
mutants and the splicing factors were distinct. I interpreted the results as that these 
splicing factors did not interact with the two critical ESE regions within LDLR exon 12. 
Instead, they influence LDLR splicing by binding to other regulatory elements. 
 
While SRp38 RNAi treatments decreased SRp38 mRNA expression by 40-50% with no 
reduction in protein level and no changes in LDLR splicing, I identified a dose-dependent 
correlation between the SRp38 mRNA expression and LDLR splicing efficiency in 
human brain and liver. Increased SRp38 expression is associated significantly with 
decreased efficiency of LDLR splicing. SRp38 affects LDLR minigene splicing 
efficiency in vitro, and its mRNA expression is correlated with LDLR splicing in vivo. 
These results indicate that SRp38 may be critical to the regulation of LDLR splicing.  
 
Model 
 
Based on the findings, I propose a model that, 1) rs688 is located close to regulatory ESE 
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regions with the rs688T allele disrupting the binding of splicing factor to the ESE 
regions, resulting in decreased LDLR splicing efficiency, producing more truncated 
LDLR; 2) SRp38 modulates LDLR splicing efficiency, with increased SRp38 levels 
resulting in more truncated LDLR and hence increases in cholesterol level and AD risk. 
(Figure 4.1) 
 
Several reasonings support this model. First, LDLR has been linked to cholesterol 
homeostasis and AD. The relationship between LDLR and cholesterol in periphery has 
been well-established. Mutations impairing LDLR function result in defects in LDLR-
mediated endocytosis, causing plasma LDL-cholesterol accumulation and developing 
familial hypercholesterolemia (Goldstein and Brown 1974; Goldstein, Dana et al. 1975; 
Hobbs, Brown et al. 1992). Individuals with elevated levels of plasma cholesterol have 
higher susceptibility to AD (Jarvik, Wijsman et al. 1995) In addition, in mouse model, 
LDLR deficiency increases brain APOE level (Fryer, Demattos et al. 2005). Since APOE 
genetic polymorphisms are highly associated with AD and APOE is involved in A  
production (Ye, Huang et al. 2005) or clearance in a receptor-dependent manner 
(Holtzman, Bales et al. 1999; Holtzman, Bales et al. 2000), LDLR as an APOE receptor 
may play a role in AD as well. Second, rs688 that modulates LDLR splicing is associated 
with cholesterol in woman and AD in men (Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 
2008). The rs688T allele increases the proportion of LDLR that lacks exon 12. The exon-
skipping causes a reading frame shift, leading to a premature stop codon in exon 13, and 
thereby a truncated LDLR without the transmembrane domain encoded by exons 16-17 is 
produced. This soluble form of LDLR can bind to ligands, but cannot process them. As a 
result, the rs688T allele is associated with higher cholesterol level and AD risk. Similarly, 
SRp38 modulates LDLR splicing efficiency as well. Ectopic expression of SRp38 
increases the proportion of LDLR that lacks exons 11 and 12, resulting in a soluble form 
of LDLR. Since SRp38 expression shows a stronger correlation with LDLR splicing 
efficiency than rs688, it is highly possible that SRp38 also modulates cholesterol level 
and AD risk. 
 
Discussion and Future Directions 
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In this study, I transfected the LDLR exon 9-14 and single exon 12 minigenes into 
HepG2 cells as in vitro models to evaluate LDLR splicing efficiency. Although the 
effects of rs688, splicing factors, and ESE mutations were consistent within these two 
minigene models, I did notice that the levels of effect were stronger for the LDLR exon 
9-14 minigene. For example, the minigene splicing efficiency between rs688C and 
rs688T alleles for the exon 9-14 minigene was about 10% different, whereas it was only 
~5% for the exon 12 minigene. In addition, the splicing pattern of the LDLR exon 9-14 
minigene with four different transcripts, i.e., FL, Delta 11, Delta 12, and Delta 11+12, 
was similar to the one I observed when quantifying the LDLR splicing in human tissues. 
Several reports have shown that for the same gene, its minigenes with different length 
construction result in different splicing patterns (Kereszturi, Kiraly et al. 2009; Mowrer 
and Wolfe 2009). Here, the rs688 allele has a lesser effect in the shorter minigene maybe 
because of the absence of neighboring regulatory elements, leading to lack of crosstalk 
between splicing factors. Therefore, to create a physiologically relevant splicing system, 
it is important to ensure that a minigene produces a splicing pattern similar to the 
endogenous gene.  
 
The first part of this study confirmed that rs688 is located close to functional ESE regions, 
and modulates LDLR exon 12 splicing efficiency. Therefore, I proposed that the 
sequences containing rs688C and rs688T allele have different affinity toward associated 
SR protein(s), and as a result, regulate LDLR exon 12 splicing. The two critical ESE 
regions are predicted to bind SRp40 and SF2/ASF respectively. However, when I 
screened the effects of splicing factors on LDLR minigene splicing, they did not enhance 
the LDLR splicing, but decreased, indicating that it is other splicing factors that interact 
with the two ESE regions. To identify the splicing factor(s) that interact with the two 
critical ESE regions may help to develop a strategy to enhance the LDLR exon 12 
splicing, overcoming the allele effect. The associated protein(s) can be distinguished by 
comparing binding proteins between wild type and mutant LDLR RNAs and identified by 
Western blots and mass spectrometry.  
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The second part of this study identified SRp20, SRp38, SRp38-2 and hnRNP G as having 
the strongest effects on LDLR minigene splicing. The ectopic expression of SRp20 
specifically increased the LDLR isoform lacking exon 11 whose expression was 
relatively low within the human tissues I examined, and I did not find that the SRp20 
expression correlated with LDLR splicing in vivo. However, a recent report has shown 
that when quantifying LDLR splicing in EBV-transformed lymphocytes from subjects, a 
fair amount of the Delta 11 LDLR was detected, and two mutations for FH at the 5‟ 
splice site of the intron 11 increased the percentage of the Delta 11 and the Delta 11+12 
LDLRs (Holla, Nakken et al. 2009). It would be interesting to investigate whether SRp20 
expression is higher in lymphocytes and whether it is involved in the recognition of 
LDLR exon 11. In addition, SRp20 expression has been reported to show a sex-
dependent difference in mice hippocampus, although I did not detect such a difference in 
human anterior cingulate. Characterization of murine SRp20 promoter revealed that 
SRp20 expression is probably regulated in a cell-specific fashion (Jumaa, Guenet et al. 
1997). Hence, it would be interesting to examine SRp20 expression in human 
hippocampus.  
 
SRp38 expression regulated the LDLR minigene splicing in vitro, and also correlated 
with LDLR splicing efficiency in vivo. I interpret the results as suggesting that SRp38 
modulates LDLR splicing. To further confirm that, I tried using siRNA and shRNA to 
inhibit SRp38 expression and evaluated effects on LDLR splicing. Unfortunately, the 
RNAi methods were not able to reduce SRp38 protein level. SRp38 has been shown to be 
activated by dephosphorylation to repress splicing. It is dephosphorylated by PP1 and 14-
3-3 keeps SRp38 from dephosphorylation (Shin and Manley 2002; Shin, Feng et al. 2004; 
Shi and Manley 2007). Therefore, to block SRp38 activity by inhibiting its 
dephosphorylation by PP1 or sequestration by 14-3-3 are alternative methods to 
investigate effect of SRp38 knockdown on LDLR splicing. 
 
Since the association between SRp38 and LDLR splicing is more robust than that 
between rs688 and LDLR splicing, and rs688 itself is associated with cholesterol and AD 
(Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 2008), I propose that SRp38 may also 
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emerge as a modulator of cholesterol homeostasis and AD risk. It would be interesting to 
investigate whether SRp38 levels correlate with cholesterol levels, and whether any 
factor, e.g. SNP, linked to SRp38 expression is also linked to AD risk.  
 
The proposed model demonstrates the importance of splicing regulation of LDLR to 
cholesterol homeostasis and AD risk. Impaired LDLR splicing regulation increases 
cholesterol level and AD risk. Therefore, a modulator for LDLR splicing may play a role 
in cholesterol homeostasis and AD as well. An interesting possibility for a future 
direction would be to screen a chemical library for molecules that modulate LDLR exon 
12 splicing. For this work, I could establish a cell-based model in the following fashion. 
First, I would generate an LDLR minigene with a reporter gene such as GFP and design 
the construct such that when Delta LDLR is produced, a stop codon is introduced before 
the GFP gene sequence, blocking GFP expression. The second step would be to generate 
a stable cell line that expresses the LDLR minigene and produces a splicing pattern 
similar to the endogenous gene. The third step would be to confirm the protein expression 
of FL and Delta LDLR by immunostaining or Western blot. The fourth step would be to 
incubate cells with or without a testing molecule and compare GFP expression. Any 
molecule increasing or decreasing fluorescence is a potential modulator for LDLR 
splicing. The cell-based model provides a fast screen for molecules that regulate LDLR 
splicing. For example, estrogen would be a good candidate to test since the association 
between rs688 and diseases is sex-dependent. This work could be done in collaboration 
with The National Institutes of Health Chemical Genomics Center (NCGC) to seek 
chemicals which enhance LDLR splicing and thereby lead to a drug discovery.  
 
Conclusion 
 
LDLR plays a central role in cholesterol homeostasis, and polymorphisms causing 
aberrant LDLR splicing have been linked to diseases such as FH and AD (Graham, 
McIlhatton et al. 2005; Zhu, Tucker et al. 2007; Zou, Gopalraj et al. 2008; Holla, Nakken 
et al. 2009). Understanding the splicing regulation can lead to discovery of novel 
molecular mechanisms underlying diseases, and possibly new therapeutic approaches. 
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However, the knowledge of LDLR splicing regulation is limited. In this study, I first 
identified two functional ESE regions with LDLR exon 12, and confirmed that rs688 is 
located close to the regulatory elements, explaining the underlying mechanism of rs688 
modulating LDLR exon12 splicing. Then, I identified several splicing factors that 
regulate LDLR minigene splicing in vitro, and among them, SRp38. Lastly, I found that 
SRp38 expression is correlated with LDLR splicing efficiency in human brain and liver. I 
interpret the results as suggesting that SRp38 may be critical in the regulation of LDLR 
splicing, and hence may also be a modulator for cholesterol homeostasis and AD risk. 
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Figure 4.1 Model of LDLR splicing regulation effects on cholesterol level and AD 
risk  
Rs688 modulates LDLR splicing. When the rs688C allele is present, more full length 
LDLR is produced and functions as a receptor for APOE-containing lipoproteins that 
transfer cholesterol in periphery and contribute to A  clearance in brain. However, when 
rs688T allele is present, more Delta 12 LDLR isoform is produced and is predicted to 
translate into soluble LDLR. The soluble LDLR still binds to APOE-containing 
lipoproteins and A  peptides, but does not mediate their internalization. As a result, 
plasma cholesterol levels and AD risk increase. Two splicing regulatory elements that 
flank rs688 are critical to LDLR splicing. The presence of rs688T allele reduces the 
affinity of these splicing regulatory elements to splicing factor(s), and therefore, 
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decreases LDLR splicing efficiency. Identifying the unknown splicing factor(s) to 
improve the interaction and enhance splicing can help to develop a strategy to overcome 
the allele effect as well as the poor 5‟ splice donor sequence. SRp38 functions as a 
splicing repressor for LDLR splicing with higher SRp38 expression correlating with less 
efficient LDLR splicing and more delta LDLR produced. Since rs688 modulates LDLR 
splicing and is associated with cholesterol level and AD risk, SRp38 being a regulator for 
LDLR splicing can be a modulator for cholesterol homeostasis and AD risk as well. 
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